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The preservation of reactive oxygen species (ROS) throughout evolution is evidence that 
ROS are critical components in immunity.  These constituents ignite a multitude of redox-
dependent pathways triggering pro-inflammatory cytokine production, dendritic cell maturation, 
and subsequent T cell activation in response to pathogen, autoimmune, and alloimmune insults.  
The aim of this thesis is to test the ability of redox modulation to suppress aberrant immune 
responses in islet transplantation.  Presently, islet transplantation is only used in desperate cases 
of glucose dysregulation due to the high failure rate of the procedure, which forces the majority 
of recipients to resume exogenous insulin within a year of islet transplantation.  Hurdles in islet 
transplantation include hypoxia during islet isolation and ischemia-reperfusion injury upon 
transplantation.  These insults result in primary non-function of islets, while harsh 
immunosuppressive agents yield islet toxicity and a multitude of complications for the recipient.   
We tested a catalytic antioxidant (CA), FBC-007, in islet transplantation based on previous work 
demonstrating that CA impairs innate-immune ROS and pro-inflammatory cytokine production 
by inhibiting NFκB-DNA binding, hinders CD4 T cell activation, and prevents the transfer of 
diabetes into young NOD.scid mice.   
First, the effects of redox modulation on CD8 T cell effector function in allogeneic and 
transgenic responses were examined in vitro.  Human islets were also used in vitro and murine 
experiments were performed in vivo to test the ability of CA to protect from streptozotocin-
induced islet cell death.  Additionally, murine islets were incubated with CA in in vivo models of 
v 
ischemia-reperfusion injury (antigen-independent) or allogeneic (antigen-dependent) 
transplantation and separately, CA was used as a systemic therapy for allograft recipients.  
Further experiments were performed to elucidate in vivo protective mechanisms of CA-
treatment.  An additional approach of interest is the induction of antigen-specific 
hyporesponsiveness to replace nonspecific immunosuppression.  A negative vaccination strategy 
delivering apoptotic donor alloantigen in a non-inflammatory adjuvant prior to allograft 
transplantation, was also tested.  Collectively, this work demonstrates 1) CA is a non-toxic, islet-
sparing, cytoprotective, and immunomodulatory agent capable of promoting islet-function,  2) 
CA impairs the alloimmune response to induce antigen-specific hyporesponsiveness, and 3) the 
negative vaccination protocol achieves long-term allograft tolerance. 
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1.0 CHAPTER 1:  INTRODUCTION 
 
 
 
1.1 TYPE 1 DIABETES 
 
Type 1 diabetes (T1D) is an autoimmune disease that is mediated by autoreactive T cells 
working in concert with macrophages to recruit inflammatory cells to islets to target and destroy 
insulin-producing β-cells of the pancreas in genetically predisposed individuals (Figure 1).  
According to the World Health Organization approximately 18 million  people suffer from T1D 
worldwide.  Though T1D is known as juvenile diabetes, the disease has been diagnosed in 
patients ranging in ages from babies under 1 year old to middle-aged adults.  T1D can be 
difficult to diagnose as untreated diabetics display symptoms similar to the flu including weight 
loss and fatigue.  In the absence of endogenously produced insulin, type 1 diabetics require 
administration of exogenous insulin multiple times a day to avoid hyperglycemia and maintain 
blood glucose levels within a normal range.  Hyperglycemia has adverse systemic effects 
resulting in chronic conditions of the nervous and circulatory systems that can lead to blindness, 
amputation of limbs, and an increased prevalence of heart attacks.  Conversely, hypoglycemia is 
more acutely dangerous in that low blood sugar can lead to seizures and a coma, which is 
especially deadly during sleep when hallmark signs of hypoglycemia-like confusion and 
dizziness go undetected. 
 Autoreactive antibodies have been characterized in patients with type 1 diabetes, though 
these markers are not steadfast and thus, not accurate enough to positively identify people who  
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Fig. 1.  Pathophysiology of type 1 diabetes. a | First, under still undefined pathogenic conditions, modified 
islet -cell antigens are released and presented by MHC class I molecules. These previously 'cryptic' antigens 
are presented by tissue-resident antigen-presenting cells (APCs) and recognized by CD8+ T cells that cause 
damage to MHC-class-I-expressing cells either through the release of cytotoxic cytokines (such as IFN-γ) or 
through the perforin–granzyme pathway. b | The released islet -cell components are taken up by immature 
dendritic cells (iDCs) in the pancreatic islets and transported to the draining pancreatic lymph nodes, where the 
antigens are processed and presented to CD4+ T cells. Lymph-node priming is thought to be the second crucial 
step leading to expansion of low frequency circulating autoreactive T cells. After clonal expansion, CD4+ 
effector T cells express adhesion molecules, such as intercellular adhesion molecule 1 (ICAM1) and 
lymphocyte function-associated antigen 1 (LFA1), and chemokine receptors, such as CC-chemokine receptor 
4 (CCR4), CCR5 and CXC-chemokine receptor 3. This allows the effector cells to home to the pancreatic 
islets, tracing antigen gradients and chemokines induced by the early CD8+ T-cell-mediated inflammatory 
response. c | Once in the pancreas, the activated CD4+ T cells recruit and activate inflammatory cells, causing 
insulitis. The effector phase of islet -cell destruction is mediated by cytokines (mainly IL-1 and TNF through 
the induction of pro-apoptotic signalling selectively in islet β-cells and/or by inducing the expression of CD95 
by islet -cells, which allows direct killing by CD95 ligand (CD95L)-expressing effector T cells. There is also 
evidence that the production of free radicals is involved in the pathogenic events leading to islet -cell 
destruction (not shown). Regulatory T cells can intervene at different stages to control type 1 diabetes. As in 
graft-versus-host disease, it is likely that regulatory T cells are first activated in the pancreatic lymph nodes. 
Activated naturally occurring forkhead box P3 (FOXP3)+CD4+CD25+ regulatory T (TReg) cells and T 
regulatory type 1 (TR1) cells, through distinct regulatory mechanisms, block the activation and expansion of 
effector T cells either directly or indirectly through APCs. Expression of adhesion molecules and chemokine 
receptors by effector T cells is also suppressed by regulatory T cells, with consequent reduced effector T-cell 
migration to the target organ. The aggressiveness of insulitis is also directly inhibited in the pancreas by 
regulatory T cells. TR1 cells, through IL-10 and (TGF-β) production, can inhibit the onset of disease and 
reduce inflammation.                                                     
From (8).  Used with permission  
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will or will not progress to clinical disease.  Upon confirmed diagnosis of hyperglycemia, 
approximately 70% of β-cells have been destroyed (6).   Since there is an absence of timely 
disease predictors or safe treatments for children, when disease onset usually occurs, 
prophylactic therapy to discourage islet destruction prior to T1D onset is not yet justified.    HLA 
Class II alleles (DRB1*03, DRB1*04, DRB1*03/04) are paramount for T1D development (9), 
though environmental factors including exposure to certain viruses and bacteria reportedly 
promote the progression of diabetes onset as evidenced by cases where only one identical twin 
succumbs to T1D (10).  Currently there is no cure for T1D, though innovations like the insulin 
pump, improved methods of monitoring blood glucose levels, better nutritional knowledge, and 
the availability of a variety of foods with a low glycemic index have improved survival rates and 
quality of life for T1D patients.  Presently, allogeneic islet transplantation is the only therapy 
able to achieve any time period of exogenous insulin independence for type 1 diabetics. 
 
1.2 ISLET TRANSPLANTATION 
 
1.2.1 Islet transplantation today 
 
Islet transplantation is a potential cure for T1D patients, however only patients with 
extreme glucose dysregulation are eligible for the procedure (11).  Even though islet 
transplantation outcomes have improved with the development of the Edmonton protocol, 
recipients rarely maintain insulin-independence for more than 2 years (12, 13).  Poor transplant 
outcomes can be attributed to the multitude of antigen-independent barriers transplanted islets 
must overcome prior to the initiation of the antigen-dependent alloimmune response.  These 
4 
antigen-independent injuries include devascularization, hypoxia, damage during isolation due to 
enzymatic digestion, donor age and cause of death, and cold storage time.  All of these factors 
contribute to some recipients requiring islets from up to 3 pancreata to achieve any period of 
normoglycemia (14).  Beyond the direct injury to islets in transplantation there is the limited 
supply of islets available for transplantation.  To refine islet transplantation, Ricordi developed a 
superior method of islet isolation.  The number of potential diabetic recipients far exceeds the 
number of donor pancreata slated for islet transplantation (14-16) as younger, healthier donors 
are typically reserved for whole organ transplantation, which has a waiting list of its own.  The 
disparity in organ quality between whole pancreas versus islet transplantation contributes to the 
requirement of multiple islet infusions to normalize a recipient and increased transplant success 
using the whole organ over islet cell transplants.  These factors, coupled with the intrinsically 
decreased antioxidant defenses of β-cells (17-22), increases islet vulnerability to inflammatory 
and free radical insults during islet isolation prior to encountering post-transplant complexities 
(15) of allograft rejection as a result of nonspecific immunosuppressive agents.   
Allograft rejection necessitates the use of potent anti-rejection drugs, though some 
commonly used immunosuppressive drugs are toxic to islets and yield undesirable complications 
including chronic infection, organ damage, and malignancy (1, 3, 11, 13, 15, 23).  Since human 
islets are delivered into the portal vein en route to the liver, the instant blood-mediated immune 
response (BMIR) leading to coagulation, complement activation and islet damage must also be 
overcome. Shapiro, et al at Edmonton outlined criteria for the islet transplant procedure that 
highlights a corticosteroid-free regimen of treatment for the transplant recipient that is less toxic 
to β-cells (13).  This collective protocol is the basis for clinical islet isolations and infusions 
worldwide (Figure 2).  
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Fig. 2.  Central concepts underlying islet transplantation. The main idea of islet 
transplantation is to process the organ donor's pancreas so as to remove the 95% of the gland 
responsible for its exocrine functions (secretion of digestive enzymes) and isolate the 5% of 
the gland responsible for the endocrine hormone secretion— the so-called pancreatic islets. 
Once isolated, the medical team can infuse the insulin-producing islets through a thin tube, 
placed in the main vein that transports blood from the intestines to the liver. Once infused, 
the islets are transported by the bloodstream into the liver, where they lodge, take up 
residence, and begin making the right amount of insulin to regulate the blood sugar.         
Illustration: Giovanni Maki                                                                                                    
From (3).  The Public Library of Science (PLoS) applies the Creative Commons Attribution 
License (CCAL) to all works we publish. No permission is required from the authors or the 
publishers. 
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1.2.2 Clinical islet transplantation:  the Edmonton protocol   
 
According to the Edmonton protocol, donor and recipient are not HLA-matched, but are 
matched for blood type and cross-matched for lymphocytotoxic antibodies.  To avoid further 
complications subtle, but critical, media additives are also used, including the use of human 
albumin instead of media containing xenoproteins.  Initially the pancreas is removed from a 
brain dead donor while the recipient begins the Edmonton regimen of corticosteroid-free 
immunosuppression prior to transplant.  Next, the pancreas is infused with cold collagenase via 
the bile duct and then placed into the Ricordi chamber for mechanical dissociation, to separate 
the islets from the exocrine tissue. Once harvested, the pancreata are maintained in cold 
University of Wisconsin solution. Islets are purified using Ficoll-diatrizoic acid in an apherisis 
system and upon purification islets are transplanted without culturing (12).  Islets are perfused 
into the portal vein to facilitate liver engraftment in medium containing 500 units of heparin and 
20% human albumin at 4000 islet equivalents (IEQ) per kilogram of the recipient’s body weight 
in the original report from Edmonton (12), though Barker, Naji, Markmann and others believe 
that more IEQ (≥ 9,000 IEQ/kg) are necessary to achieve increased periods of insulin-
independence (11, 24).  Any additional success accompanying an increase in IEQ/kg is most 
likely attributed to increased islet survival after islet loss from hypoxia, isolation-induced stress 
and post-transplant ischemia-reperfusion injury.  Due to perfusion into the portal vein, BMIR is 
treated with heparin and complement inhibitors, but the antigen-specific T cell-mediated 
alloimmune response is not easily overcome requiring potent immunosuppressive-agents to 
inhibit allograft rejection. 
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1.2.3 Allograft rejection 
 
Damage incurred during the islet isolation process is a prominent reason why whole 
pancreas transplantation is more successful than islet transplantation, as a whole organ is 
manipulated less and retains vascularization within the organ (25).  However, in a cell or whole 
organ transplant, removing the pancreas from the donor initiates hypoxia and activation of 
antigen-independent innate immune ligands through TLR activation.  Innate immune activation 
results in the release of reactive oxygen species and pro-inflammatory cytokines which facilitates 
an adaptive immune response (2, 5, 7, 26-29).  Activation of innate immune ligands induces 
APC maturation, bridging the innate and adaptive immune systems (2, 5, 7, 26-29).  Taken 
together, antigen-independent inflammatory damage incurred during islet isolation and ischemia-
reperfusion injury exacerbates antigen-dependent allograft rejection by triggering inflammatory 
signals required for adaptive immune function.  
Professional antigen presenting cells (APC), such as DCs, phagocytose allopeptide shed 
from the graft and migrate to the draining lymph nodes to activate naïve allospecific T cells 
through (1) peptide:MHC:TCR engagement and (2) co-stimulatory molecule interactions 
between the T cell and the activated DC, which matures as a result of (3) the synthesis of pro-
inflammatory innate immune ligands (26-32).  The third signal is a culmination of innate 
immune-derived pro-inflammatory cytokines and ROS and is a precursory requirement with 
respect to the two other signals for both DC maturation and subsequent T cell activation (Figures 
3 and 4).   
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Reprinted, with permission, from the Annual Review of Immunology, Volume 19 (c) 2001 by 
Annual Reviews www.annualreviews.org<http://www.annualreviews.org> 
2001 by Annual Reviews (www.annualreviews.org) and from Dr. Marc Jenkins 
Fig. 3. 
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induced 
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Fig. 4. 
Diagrammatic 
representation 
of an 
unproductive 
CD4 T cell 
response to 
antigen in the 
absence of 
inflammation. 
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Allograft rejection occurs through two distinct pathways, the direct and indirect pathways 
(Figure 5B).  In the direct pathway, mature donor DC (passenger leukocytes) migrate to lymph 
nodes to present their allospecific MHC to allospecific recipient T cells.  The indirect pathway 
contributes to rejection when mature recipient DCs process and present alloantigen to 
allospecific recipient T cells.  Through either pathway, the end result is activated allospecific T 
cells which engage in acute allograft rejection by acquiring effector function and homing to the 
site of the allograft to destroy the alloantigen-expressing donor islets (5).  The critical difference 
between immune settings of self-tolerance or allograft rejection correlates to a steady state or 
inflammatory immune environment, respectively, which dictates the activation/maturation state 
of DCs (Figure 5A).  Even if acute rejection is overcome, the allograft is a constant source of 
alloantigen that will repeat the activation process to prime allospecific T cells resulting in 
chronic rejection.   
Within these processes, CD8 T cells directly participate in islet death via target cell lysis. 
CD4 T cells play a role in allograft rejection indirectly by further activating macrophages and B 
cells and by providing T cell help to CD8 T cells by up-regulating co-stimulatory molecules 
through APC interactions and the synthesis of TH1 and TH17 pro-inflammatory cytokines, like 
IFN-γ and IL-17.  It is also possible that CD4 T cells interact directly with CD8 T cells to 
enhance the alloimmune response.  At the site of the graft, CD4 T cells initiate pro-inflammatory 
cytokine production by macrophages (reactive oxygen species, TNF-α and IL-1β) to induce 
direct and indirect islet cytotoxicity, and subsequently, islet dysfunction and death.  Most 
notably, the combination of IFN-γ from CD4 T cells and IL-1β and TNF-α from macrophages 
prompts β-cell apoptosis, but this combination of cytokines also promotes CD8 cytotoxic 
lymphocyte (CTL) migration to the allograft (6).  Additionally, CD4 T cells activate B cells,  
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Fig. 5. Role of dendritic cells (DCs) in peripheral tolerance and graft rejection. (A) During steady-state 
conditions (absence of pro-inflammatory or danger signals), peripheral tissue-resident DCs capture self-
antigens from neighboring parenchymal cells via uptake of apoptotic cells, vesicular exchange with living 
cells, or endocytosis of soluble molecules. DCs mobilize [likely as semi-mature antigen-presenting cells 
(APCs)] via lymphatic or blood vessels from the periphery to T-cell areas of secondary lymphoid organs. 
Once there, DCs present self-antigens to autoreactive T cells that escaped thymic selection. Under 
physiological conditions, DCs in T-cell areas of spleen or lymph nodes express low levels of T-cell co-
stimulatory molecules and induce a transient and weak proliferation of autoreactive T cells followed by T-cell 
deletion, anergy, and, probably, generation of Treg cells. (B) Following transplantation surgery, pro-
inflammatory mediators released locally, ischemia–reperfusion injury, and the presence of necrotic cells 
trigger full maturation of donor DCs (donor tissues and cells are in red) and recipient DCs (recipient cells are 
in blue) that infiltrate the graft as part of the inflammatory reaction. Both donor- and recipient-derived DCs 
migrate out of the graft as passenger leukocytes. Once in the T-cell area of the secondary lymphoid organs, 
mature donor DCs present allo-major histocompatibility complex (MHC) molecules to alloreactive T cells 
(direct pathway) and mature recipient DCs present allopeptides loaded into self-MHC molecules to recipient T 
cells recognizing allopeptides in the context of self-MHC molecules (indirect pathway). 
From (5).  Used with permission 
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Fig. 6.  Model for the role of innate TLR-dependent immunity in acute allograft 
rejection. Donor organ harvest and implantation results in ischemia-reperfusion injury that 
may be mediated by TLR signaling and release innate immune ligands. These ligands allow 
DCs (donor or recipient) to mature and migrate to the draining lymph nodes. The maturation 
of DCs leads to the production of proinflammatory cytokines that aid in naïve T cell 
priming and render the generated effector T cells resistant to host suppressive mechanisms. 
The armed effectors than initiate acute graft rejection. 
Modified from (3, 7).  Used with permission.  
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propagating further inflammation and islet death through antibody-mediated responses to the 
allogeneic islet graft.  The concert of these mechanisms leads to destruction of the islet allograft 
in the absence of immunosuppression (Figure 6), though graft failure often occurs in spite of 
treatment with anti-rejection drugs. 
 
1.2.4 Immunosuppressive anti-rejection drugs 
 
Due to the alloimmune response, immunosuppression of the recipient is required to  
protect from graft destruction.  The T cell precursor frequency for alloantigen (<1/10,000) is 
immensely higher compared to the precursory frequency of T cells specific for a nominal antigen 
(1/200,000) (33-35).  Therefore, immunosuppression must be very potent to control an 
allogeneic response after transplantation.  Current anti-rejection drugs used to restrain the 
alloimmune response, like sirolimus and tacrolimus (Figure 7), are nonspecific and suppress 
immune function globally.  Additionally, the majority of these immunosuppressive agents target 
the T cell and the adaptive immune response, though it is well-known that the activation state of 
the APC shapes the adaptive immune response (2, 5, 7, 29, 36).  The depressed state of the 
immune system under immunosuppression often leads to complications including cancer, 
chronic infection and organ damage.  More specifically, commonly used anti-rejection drugs 
induce β-cell toxicity, adding another hurdle when striving to achieve graft survival. 
According to the Edmonton protocol, the recipient is treated with glucocorticoid-free 
immuosuppression prior to islet transplantation including a loading dose of sirolimus, low-dose 
tacrolimus (FK506), and daclizumab (anti-CD25). Prophylactic antibiotics (vancomycin and 
imipenem) are administered prior to transplant and so are the antioxidants, vitamin E, vitamin 
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B6, and vitamin A, in attempt to impair free radical production (37).  Post-transplant maintenance 
concentrations of sirolimus and tacrolimus are generally maintained and 4 more doses of 
daclizumab, inhaled pentamidine once a month to avert pneumocystis, and ganciclovir for 14 
weeks to avert cytomegalovirus and lymphoproliferative disease are also administered.  Initially, 
this protocol sustains allograft function as demonstrated by insulin-independence and euglycemia 
(12).  However, in a five-year follow-up study of islet transplant recipients under the Edmonton 
group, only 5 recipients were normoglycemic after one transplant, 52 patients required two 
transplants, and 11 patients required three transplants to achieve insulin independence for any 
length of time.  The average duration of insulin independence for all transplant recipients was 
only 15 months.    
 
 
 
 
 
 
 
 
 
 
 
 
   
Fig. 7. Individual immunosuppressive drugs and sites of action 
From (1).  Used with permission. 
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The authors concluded that there is a need for improved islet engraftment and function in 
addition to the need for novel immunosuppressive drugs uncoupled to toxicity and other harmful 
side effects like hypertension, fungal pneumonia, and malignancy.  These side effects can 
compromise the transplant and lead to transplant rejection, namely when the side effect requires 
immunosuppressive regimens to be reduced or eliminated.  In the current state of islet 
transplantation, which is inseparably coupled to complications, an islet transplant may be more 
of a detriment than of benefit, especially for patients with poorly controlled glucose levels, but 
preserved kidney function (3).  The development of superior immunosuppressives and new 
protocols to preserve islet viability and function during isolation and engraftment could greatly 
benefit recipients of islet allografts by promoting long-term insulin-independence and limiting 
transplant-associated complications. 
 
1.2.5 Difficulties resulting from islet isolation 
 
 In transplantation, islets are increasingly exposed to free radical and inflammatory insults 
compared to whole pancreas transplantation.   When a pancreas is excised from donor circulation 
for a whole organ transplant, vasculature is maintained, however, when a pancreas is excised for 
islet transplant, the organ endures further manipulation including removal of the organ’s 
vasculature and pancreatic lymph, which promotes allograft tolerance (25).  Both whole pancreas 
and islet transplants incur hypoxic and ischemia-reperfusion injury, though islets must also 
withstand the process of isolation.  Islet isolation is a conundrum as it equates to a less-invasive 
procedure compared to whole pancreas transplantation, though the islet purification process is 
harmful to β-cell function and viability.  Islet isolation entails additional hypoxic time and 
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subsequent inflammatory damage fueled by reactive oxygen species and pro-inflammatory 
cytokines generated by islets, acinar tissue, and resident leukocytes antigen-independent innate-
mediated injury.  Since antigen-independent, nonspecific inflammatory damage results in 
primary β-cell non-function and death, cytoprotection of islets is needed during islet isolation 
and transplantation.  The benefits of cytoprotection are repeatedly touted in the literature, but 
without notable recourse that is practical for use in clinical islet transplantation (2, 15, 38-40). 
    
1.3  REDOX MODULATION BY THE CATALYTIC ANTIOXIDANT, FBC-007 
 
Controlling the innate immune response in the context of allograft transplantation is of 
increasing interest as more investigators appreciate the role of a mature or immature APC/DC to 
impart immunity or tolerance, respectively (7, 41-43).  There is an overwhelming request for 
cytoprotective agents for islet allografts, which must endure islet isolation and nonspecific 
inflammatory cascades prior to post-transplant ischemia-reperfusion injury and the onslaught of 
the alloimmune response (2, 15, 38-40, 44).  These compounding factors necessitate an approach 
in islet transplantation that is cytoprotective, immunomodulatory, and antigen-specific to achieve 
long-term, consistent success in islet transplantation.   
Redox modulation is capable of addressing several unresolved issues in allograft 
transplantation since it targets both the innate and adaptive immune systems.  The agent used as 
a molecular probe of redox modulation is the catalytic antioxidant (CA) FBC-007, which is 
comprised of a metaloporphyrin ring with a manganese ion in the center (Figure 8).  CA can 
scavenge and dissipate a broad range of ROS (4, 45-48) and displays oxido-reductase activity in  
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the ability to oxidize and reduce redox-sensitive proteins to exert immunomodulatory effects 
depending upon the redox environment.   
Specifically, CA inhibits the redox-sensitive transcription factor, NF-κB, by oxidizing 
cysteine 62 of the NF-κB p50 DNA binding site subunit to prevent DNA binding and expression 
of NFκB-dependent gene transcription in the nucleus (48).  Impairment of NF-κB activation is 
responsible, in part, for downstream effects of CA-treatment including the ability of CA to block 
the adoptive transfer of type 1 diabetes in young NOD.scid mice using a diabetogenic T cell 
clone (49), to suppress the production of ROS, TNF-α and IL-1β in LPS-stimulated 
 
 
 
Fig. 8.  Structure of FBC-007/CA also known as (manganese(II) tetrakis (N-
ethylpyridium-2-yl) porphyrin). R groups for FBC-007/CA shown in the black box. 
From (4). Used with permission. 
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macrophages and DC (48), and to impair the production of TNF-α thereby disrupting the 
transition of T cell expansion to effector function (26).  CA can be used as islet-directed 
(cytoprotection) or systemically (immunomodulatory) in small molecule form.  Additionally, 
human islets treated with CA during islet isolation or in culture preserve islet function and 
viability (38, 39).  The benefits of redox modulation using CA warrant use in allograft 
transplantation when considering the cytoprotective properties of CA and its ability to inhibit 
innate and adaptive immune effector function without inducing toxicity (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Simplified schematic illustration of intracellular TLR-triggered/mediated 
signaling pathways resulting, via activation of transcription factors, in the expression 
of “innate” genes involved in inflammation, antiviral responses, and maturation of 
DCs with respect to allograft injury and rejection pathways.  
From (2). Used with permission. 
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2.0  CHAPTER 2:  REDOX MODULATION INHIBITS 
CD8 T CELL EFFECTOR FUNCTION 
 
2.1  ABSTRACT 
 
The evolutionary preservation of reactive oxygen species (ROS) in innate immunity 
underscores the important roles these constituents play in immune cell activity and as signaling 
intermediates.  In an effort to exploit these pathways to achieve control of aberrant immune 
activation we demonstrate that modulation of redox status suppresses cell proliferation and 
production of IL-2, IFN-γ, TNF-α, and IL-17 in two robust CD8 T cell-dependent in vitro mouse 
models:  (1) response to alloantigen in an mixed leukocyte reaction (MLR) and (2) CD8 T cell 
receptor transgenic OT-1 response to cognate peptide (SIINFEKL).  To correlate these findings 
with (cytotoxic lymphocyte) CTL function we performed cytotoxicity assays and found that 
redox modulation diminishes the ability of alloantigen-specific and antigen-specific OT-1 CTLs 
to kill their corresponding antigen-expressing target cell.  To further examine mechanisms of 
redox-mediated repression of CTL target cell lysis, we analyzed expression of the effector 
molecules IFN-γ, perforin, granzyme B, and the degranulation marker, CD107a (LAMP-1).  In 
both models, redox modulation reduced expression of these effector components by at least 5-
fold.  These results demonstrate that redox modulation quells the CD8 T cell response to 
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alloantigen and the T cell receptor transgenic CD8 T cell response to its cognate antigen by 
inhibiting proliferation, pro-inflammatory cytokine synthesis, and CTL effector mechanisms. 
 
2.2 INTRODUCTION 
 
Reactive oxygen species (ROS) are one of the immune system’s oldest yet most effective 
first lines of defense involved in the eradication and control of infectious agents. Throughout 
evolution, ROS generated during early events in immune system activation have remained an 
integral part of a complex immune response.  In addition to their capacity to directly kill 
microbes, ROS are critical signaling intermediates linking the innate and adaptive immune 
systems by triggering the production of pro-inflammatory cytokines (TNF-α, IL-1β), termed 
third signal molecules, by macrophages and DCs (dendritic cells) of the innate immune system.  
There is growing interest in molecular pathways and signaling mediators linking the innate and 
adaptive arms of the immune response (50-52) as the innate immune-derived third signal, 
required for maturation of the adaptive immune response, is dependent on the redox-sensitive 
signaling pathways MAPK, AP-1 and NF-κB (27, 28, 48, 50-54).   
The events of third signal synthesis leading to APC (antigen presenting cell) activation 
can occur through the binding of toll-like receptors to microbial pathogen associated molecular 
patterns (PAMPs) (50-52), the generation of pro-inflammatory cytokines (27, 28, 55, 56), or 
through natural adjuvants that are endogenous activators of APC (57).  NF-κB activation of 
APCs results in third signal pro-inflammatory cytokine production and contributes to the up-
regulation, maturation, and immunostimulatory capability of co-stimulatory molecules (CD40, 
CD80, CD86) on DC (42, 58-64).  Accordingly, this pro-inflammatory third signal is required for 
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optimizing signal 1 (T cell receptor (TCR), peptide and major histocompatibility complex 
(MHC) engagement) and signal 2 (co-stimulatory molecule interaction) among APCs and naïve 
T cells.  These events, together with IL-12 production by activated, mature DCs, are required to 
drive naïve T cells to effector function (29, 54, 65).   
We have shown that modulating redox balance using a non-toxic, cell-permeable 
catalytic antioxidant probe FBC-007 (manganese (II) tetrakis (N-ethylpyridium-2-yl) porphyrin) 
(CA) led to suboptimal APC priming and inefficient activation of the diabetogenic CD4 T cell 
clone BDC2.5, thereby preventing the adoptive transfer of type 1 diabetes to young NOD.scid 
mice (49).  The CA compound is comprised of a metal center that catalyzes the dismutation of 
O2-, mimicking the active metals in naturally occurring mammalian Cu, Zn, or Mn SODs (66-
68), harnessing the ability to scavenge several oxidants including superoxide, hydrogen peroxide, 
peroxynitrite, and lipid peroxyl radicals (4, 26, 45-48, 66).  Manganese metalloporphyrins (CA) 
display oxidoreductase activity and can oxidize redox-sensitive transcription factors such as NF-
κB, AP-1, and HIF-1 without inducing toxicity.  Accordingly, CA is able to avert endotoxic 
shock (69), excitotoxic neuronal cell death (70) and apoptosis (71), lipid peroxidation (4), 
peroxide-induced mitochondrial DNA damage (72), and significantly prolongs survival in 
phenotype lethal manganese superoxide dismutase knockout mice (26, 48, 73).  Additionally, 
these compounds have been shown to reduce other inflammatory-mediated diseases by limiting 
oxidative stress in various in vivo rodent models including cancer (74), amyotrophic lateral 
sclerosis (75), and ischemia and reperfusion injury (76).  Our mechanistic analysis of CA-
mediated inhibition of APC function revealed that CA acts as an oxidoreductase, affecting the 
innate immune response of APCs by inhibiting NF-κB-DNA binding and the synthesis of the 
NF-κB-dependent pro-inflammatory cytokines, TNF-α and IL-1β, which are necessary for 
21 
immune cell maturation and for T cells to transition to effector function (27, 28, 48).  Most 
recently, we observed that altering redox balance affects adaptive immune function as 
demonstrated by decreased antigen-specific CD4 T cell proliferation and type 1 polarizing 
cytokine synthesis (TNF-α and IFN-γ) as well as the induction of an antigen-specific hypo-
responsive T cell population (26).  
The focus of this study is to determine if redox modulation, which is known to inhibit 
APC and CD4 T cell function (26, 48), has a marked effect on CD8 T cell function in the 
presence or absence of CD4 T cell help.  CD4 T cells indirectly augment CD8 T cell function by 
inducing increased APC immunostimulatory capability through signal 1 engagement.  More 
specifically, increased expression of co-stimulatory molecules on APC, resulting from signal 1 
engagement with CD4 T cells, generates a more potent APC which is able to stimulate naïve 
CD8 T cells to transition to effector function (77).  Additional evidence demonstrates that CD4 T 
cells can directly interact with CD8 T cells through CD40L-CD40 interactions, respectively, to 
enhance CD8 T cell maturation (78).  Our initial studies demonstrating that redox modulation 
affects CD4 T cell activation and effector function (26), combined with the knowledge that CD8 
T cell maturation and effector function is linked to optimal CD4 T cell help, led to the hypothesis 
that redox modulation would have marked effects on CD8 T cell activation and effector function 
either directly or indirectly, through impaired CD4-derived T cell help. 
To examine if redox modulation can affect CD8 T cell function we employed 
alloantigen-specific and transgenic in vitro mouse models representative of increased T cell 
precursor frequencies compared to that of a nominal antigen in the presence or absence of CD4 T 
cell help.  For the first model we generated alloantigen-specific CTLs (cytotoxic lymphocytes), 
inclusive of CD4 T cell help, in a mixed leukocyte reaction (MLR) using MHC-mismatched 
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C57BL/6J (C57BL/6, H-2b) responders and BALB/cByJ (BALB/c, H-2d) irradiated stimulators.  
In the second model we determined if redox modulation had a more direct effect on CD8 T cell 
effector function using the antigen-specific OT-1 T cell receptor transgenic mouse model, 
dominantly comprised of OVA peptide257-264 (SIINFEKL)-specific CD8 T cells (79), in which 
CD4 T cell help is not necessary, nor available, to augment adaptive immune effector function.  
Using the two CTL models we demonstrate that redox modulation has a profound effect on T 
cell proliferation, pro-inflammatory cytokine production, and CTL target cell lysis by reducing 
the expression of cytolytic effector molecules. 
 
2.3  MATERIALS AND METHODS 
 
2.3.1  Mice and cell lines 
 
OT-1 T cell receptor transgenic mice were bred and housed under specific pathogen-free 
conditions in the Animal Facility of the Rangos Research Center at the University of Pittsburgh.  
OT-1 CD8 T cells are transgenic for a TCR specific for a class I-restricted OVA peptide257-264 
(SIINFEKL-Kb) (79). C57BL/6J (C57BL/6, H-2b) and BALB/cByJ (BALB/c, H-2d) mice were 
purchased from The Jackson Laboratory.  Six to eight week old female mice were used in all 
experiments.  All mouse studies were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Pittsburgh.  EL-4 and EG.7 cell lines were 
purchased from ATCC (Manassas, VA).  EL-4 cells were grown in complete media (CM) 
(DMEM supplemented with 10% heat-inactivated FBS, 10 mM HEPES buffer, 4 mM L-
glutamine, 200 µM nonessential amino acids, 1 mM sodium pyruvate, 61.5 µM 2-ME, and 100 
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µg/ml Gentamicin (Invitrogen Life Technologies, Carlsbad, CA)) and allowed to grow to 106 
cells/ml in a 75 cm2 tissue culture flask (Cellstar, PGC Scientific, San Diego, CA) prior to 
passing.  EG.7 cells were grown in CM with 0.4 mg/ml G418 (Sigma-Aldrich, St. Louis, MO) 
and allowed to grow to 106 cells/ml in a 75 cm2 flask prior to passing. 
 
2.3.2  Reagents 
 
The catalytic antioxidant (CA), FC-007, a kind gift from Dr. James Crapo at National 
Jewish Research and Medical Center (Denver, CO), was re-suspended in HBSS with Ca2+ and 
Mg2+ (Invitrogen Life Technologies) at a stock concentration of 2 mM and filter sterilized (.2µm 
cutoff) before use.  The final concentration of CA used for all experiments was 68 µM as 
previously published (48).  Chicken OVA257-264 (SIINFEKL) was purchased from Sigma-Aldrich 
and used at a final concentration of 1µM.  CD4, CD8, IL-2 receptor α-chain (CD25), CD107a 
(LAMP-1), IFN-γ, granzyme B, perforin, and Foxp3 fluorochrome-conjugated antibodies were 
purchased from BD Biosciences (San Jose, CA).  
 
2.3.3  Mixed Leukocyte Reactions (MLRs) 
 
Unidirectional MLRs were performed by co-culture of 106 C57BL/6 splenocyte stimulators 
(irradiated with 3000 rads) with 106 BALB/c splenocyte responders as described by (80) with 
minor modification.  Cytokine analysis of MLR supernatants was performed by ELISA and 
intracellular cytokine analysis of cytotoxic lymphocytes (CTLs) was performed in 96-well, 
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round-bottom plates with or without 68 µM CA in a final volume of 200 µl CM and incubated 
for 1 to 5 days under normal conditions (37°C in a 5% CO2 humid air incubator).   
 
2.3.4  OT-1 assays 
 
105 OT-1 splenocytes (unless otherwise noted) and 1 µM SIINFEKL peptide were plated 
with or without 68 µM CA at a final volume of 200 µl CM in a 96-well, round-bottom plate and 
incubated for 1, 2, or 3 days under normal conditions.  
 
2.3.5  In vitro cell proliferation  
 
For proliferation assays, 96-well MLR were prepared as described above and incubated 
for 5 days.  5 x 105 OT-1 splenocytes were plated in 96-well, round-bottom plates and incubated 
for 2 or 3 days.  For MLR and OT-1 assays, [3H]TdR was incorporated on day 5 (MLR) or days 
2 and 3 (OT-1) by pulsing wells with 1 µCi of [3H]TdR for 18 h, freezing plates for 18 h, 
followed by thawing plates before samples were harvested onto glass fiber filters using a sample 
harvester.  The amount of incorporated counts was determined using a beta scintillation counter. 
 
2.3.6  Cytokine measurements by ELISA  
 
MLR assays were performed as described above and supernatants were harvested on days 
1 through 5 to measure IL-2, IFN-γ, TNF-α, and IL-17 production by ELISA.  OT-1 assays were 
performed as described above and supernatants were harvested on days 1, 2, and 3 to measure 
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IL-2 and IFN-γ production by ELISA.  In order to detect OT-1-derived TNF-α by ELISA, 5 x 
105 OT-1 splenocytes were plated and supernatants were harvested on days 1, 2, and 3.  IL-2 and 
IFN-γ, produced in supernatants of 96-well MLR and OT-1 assays, were measured using 
antibody pairs from BD Pharmingen (San Diego, CA).  TNF-α and IL-17 cytokine analysis of 
both assays was performed using DuoSet ELISA kits (R & D Systems, Minneapolis, MN).  
ELISA plates were read on a Spectromax M2 microplate reader (Molecular Devices, Sunnyvale, 
CA) and data were analyzed using Softmax Pro v5.0.1 (Molecular Devices).   
 
2.3.7  Cytotoxicity assay by DELFIA 
 
For MHC-mismatched cytotoxicity assays, a primary MLR was performed as described (80, 81) 
with minor modification, using 2.5 x 106 BALB/c responders and 2.5 x 106 C57BL/6 irradiated 
stimulators in 24-well plates in a final volume of 2 ml CM in the presence or absence of 68 µM 
CA for 5 days under normal conditions.  On day 5, treated and untreated cytotoxic lymphocytes 
(CTLs) were harvested using cell dissociation buffer (Invitrogen Life Technologies).  
Simultaneously, EL-4 (H-2b) target cells were labeled with BATDA-reagent and the cytotoxicity 
assay was performed according to manufacturer’s protocol in the DELFIA kit (AD0116: 
PerkinElmer, Inc, Waltham, MA).  10,000 EL-4 targets were incubated with cytotoxic 
lymphocytes (CTLs) at 50:1 and 100:1 effector to target ratios for 2 h.  Fluorescence of the 
supernatant was measured in a time-resolved fluorometer.  DELFIA data are presented as 
“percent specific release” based on the formulae in the manufacturer’s protocol representing 
specific lysis of targets cell by effector cytotoxic lymphocytes (CTLs).   
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For OT-1 antigen-specific CD8 cytotoxicity assays, the DELFIA kit was also used. C57BL/6 
splenocytes were irradiated at 3000 rad leaving viable APCs.  Five x 106 splenocytes were 
incubated with 1 µg/ml LPS in 24-well flat-bottom plates in a final volume of 2 ml for 3 days 
under normal conditions to activate the radio-resistant APCs.  On day 3, the LPS-activated 
C57BL/6 APCs were pulsed with 5 µM SIINFEKL for 30 min under normal conditions and then 
washed twice with CM.  OT-1 CD8+ T cells were purified from whole spleen by negative 
selection using CD4+ and MHC class II magnetic beads (Miltenyi Biotec, Auburn, CA) 
according to the manufacturer’s protocol.  2.5 x 106 LPS-activated SIINFEKL-pulsed C57BL/6 
APCs were incubated with 2.5 x 106 OT-1 T cells with or without 68 µM CA in a 24-well flat-
bottom plate in a final volume of 2 ml CM under normal conditions for 4 days.  On day 4, 
cytotoxic lymphocytes (CTLs) were harvested and plated with 10,000 target cells at a 50:1 
effector to target ratio according to manufacturer’s protocol.  Two h later supernatants were 
harvested and fluorescence was measured by a time-resolved fluorometer.  Again, data are 
presented in “percent specific release” as indicated above. 
 
2.3.8  Flow cytometric analysis 
 
Cells were washed in filter-sterilized FACS buffer (1% bovine serum albumin (BSA) in 
phosphate buffered saline (PBS)) and re-suspended in FACS buffer at the final concentration of 
107 cells/ml.  One million cells were stained with directly fluorochrome-conjugated antibodies at 
the appropriate dilution (10 µl of each antibody) in FACS buffer for 20 min in the dark at 4°C.  
Cells were washed in FACS buffer before measuring fluorescence on a FACSCalibur (BD 
Biosciences).  
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2.3.9  Annexin V viability experiments 
 
For annexin V viability experiments of whole spleen, 96-well MLRs were prepared as 
previously described and incubated for 1, 3, or 5 days.  At each time point cells were harvested, 
washed twice in PBS, re-suspended in FACS buffer, and stained with PE-conjugated annexin V 
antibody (BD Biosciences) before fluorescence was measured as described above.  For annexin 
V staining of the T cell population, assays were performed in the same manner with the addition 
of an APC-conjugated CD8 antibody (BD Biosciences) stain for all time points. 
 
2.3.10  Intracellular ROS detection by CM-H2DCFDA  
 
2 x106 OT-1 splenocytes were stimulated with 1 µM SIINFEKL, or left un-stimulated, in the 
presence or absence of 68 µM CA in 24 well plates.  After 24 hours, cells were harvested and 
loaded with 5µM FITC-conjugated CM-H2DCFDA dye (Molecular Probes) for 30 minutes at 
37°C.  Some cells were not stained with the dye, and only incubated for 30 minutes at 37°C, as 
unstained FACS controls.  All cells were then washed twice in CM and re-suspended at 107 
cells/ml in FACS buffer.  One million cells were stained with PECy5-conjugated CD8 antibody 
or left unstained to serve as appropriate controls according to previously mentioned methods.  
Results are presented as delta (Δ) percent CD8 x CM-H2DCFDA double positive cells with 
respect to un-stimulated OT-1 controls. 
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2.3.11  Trypan blue exclusion viability experiments 
 
For trypan blue viability assays, 96-well MLRs were prepared as previously described and 
incubated for 1, 3, or 5 days.  At each time point cells were harvested, washed twice, and re-
suspended in PBS.  For each of the groups, a 10 µl cell aliquot was diluted 1:10 in 100 µl and 
added to 20 µl of trypan blue.  Cell samples were vortexed before a 10 µl sample was pipetted 
into a hemocytometer under a light microscope.  Live and dead cells were counted in at least two 
quadrants for each group at each time point.  Results are reported as percent live cells per 
quadrant equivalent to number of live cells /total number of cells.   
 
2.3.12  Intracellular staining and FACS analysis 
 
Intracellular staining was measured in CA-treated and untreated cells in MLR and OT-1 
assays on days 1, 2, 3 with the aid of the Murine BD intracellular cytokine staining kit (BD 
Biosciences).  After stimulation, splenocytes were surface-stained with PECy5 or APC-
conjugated CD8 and FITC-conjugated CD107a (LAMP-1) then fixed in BD Cytofix/Cytoperm 
buffer, washed in BD Perm/Wash buffer, and then stained intracellularly with APC-conjugated 
rat anti-IFN-γ, APC-conjugated rat-anti-perforin or PE-conjugated rat-anti-granzyme B (BD 
Biosciences).  The appropriate isotype controls were used.  Cells were washed twice in BD 
Perm/Wash buffer and re-suspended in FACS buffer; stained cells were analyzed on a 
FACSCalibur (BD Biosciences).  
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2.3.13  Statistical analysis  
 
The difference between mean values for each experimental group was determined by a Student’s 
t test, with p < 0.05 for significance, using the JMP statistical discovery software from the SAS 
Institute.  All experiments were performed at least three separate times with data obtained from 
triplicate wells in each experiment; the only exception being FACS analysis in which data are 
representative of at least three independent experiments. 
 
2.4  RESULTS 
 
2.4.1  Redox modulation suppresses cell proliferation and the production of IL-2, IFN-γ, 
TNF-α , and IL-17 in a primary Mixed Leukocyte Reaction (MLR) 
 
Based on our prior studies showing that redox modulation of the innate immune-derived 
pro-inflammatory third signal diminishes the expansion and effector function of antigen-specific 
CD4 T cells (26), we initiated studies to determine if redox modulation would also affect the 
response to alloantigen that is mediated by both, CD4 and CD8 T cells.  We performed in vitro 
unidirectional MLRs by co-culturing 106 MHC-mismatched BALB/c (H-2d) responders with 106 
C57BL/6 (H-2b) irradiated stimulators in the presence or absence of a predetermined 
concentration of CA (68 µM) capable of suppressing production of innate immune-derived pro-
inflammatory cytokines (48).  Figure 10A demonstrates a significant three-fold decrease in 
proliferation with redox modulation by day 5 in an MLR assay.  Along with reduced 
proliferation, redox modulation suppresses the production of IL-2 in MLR supernatants by two-
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fold at the same time point (Figure 10B). Taken together redox modulation inhibits T cell 
proliferation and IL-2 production in vitro.                             
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Fig. 10.  Redox modulation suppresses cell proliferation and cytokine production in a 
primary MLR.  In a primary MLR, 106 BALB/c splenocytes were stimulated with 106 
irradiated C57BL/6 splenocytes in the presence () or absence () of 68 µM CA for up to 5 
days.  On day 5 proliferation was assessed by [3H] TdR incorporation (A).  On days 1-5 
supernatants were harvested and IL-2 (B), IFN-γ (C), and TNF-α (D) were measured by 
ELISA.  Results are presented as the mean (± SEM) of four independent experiments 
performed in triplicate.  **, p < 0.05 between the respective treated and untreated (control) 
group. 
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To gain further insight into the T cell effector response to alloantigen, IFN-γ production 
was analyzed in MLR supernatant in the presence or absence of redox modulation.  We observed 
a statistically significant 6-fold decrease in IFNγ levels in CA-treated MLR on Days 3, 4, and 5 
compared to untreated MLR (Figure 10C).  To determine if TNF-α, an upstream stimulus of 
IFN-γ production, was also reduced in the presence of redox modulation (26, 82), TNF-α levels 
were measured by ELISA in untreated and CA-treated MLR supernatants.  We observed 
significant decreases in TNF-α levels from CA-treated samples on days 2-5 (Figure 10D), 
concomitant with suppressed IFN-γ levels with CA-treatment. In addition, we observed a 
significant 3-fold repression of the pro-inflammatory cytokine, IL-17, in CA-treated MLRs on 
Days 2, 3, 4, and 5 (Figure 10E).  IL-17 is a cytokine of interest due to its documented role in 
allograft rejection and indispensable role in autoimmune diseases (83-89).  In agreement with 
several studies (90-93), our data reflects the simultaneous presence of functional TH1 and TH17 T 
cells in response to an alloantigen.    
 
2.4.2  Redox modulation impairs the ability of alloantigen-specific cytotoxic lymphocytes 
(CTLs) to kill MHC-mismatched target cells  
 
To determine if the redox-dependent decreases in IL-2, IFN-γ, ΤΝF-α, and IL-17 in 
response to alloantigen equates to an appreciable effect on CTL-induced target cell lysis, CTLs 
were generated by MLR in the presence or absence of redox modulation.  BALB/c CTLs (H-2d) 
were harvested to determine the capacity of CA-treated and untreated CTLs to kill MHC-
mismatched EL-4 (H-2b) target cells.  At effector to target ratios of 100:1 and 50:1,                 
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BALB/c CA-treated CTLs exhibited a 3-fold decrease in the ability to kill EL-4 target cells 
compared to control CTLs (Figure. 11).  
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Figure 2. Redox modulation diminishes the ability of alloantigen
specific CTL to kill targets in a cytotoxicity assay
 
Fig. 11.  Redox modulation diminishes the ability of alloantigen-specific CTLs to kill 
their MHC-mismatched target cells in a cytotoxicity assay.  Alloantigen-specific CTLs 
were derived by stimulating 2.5 x 106 BALB/c (H-2d) splenocytes with 2.5 x 106 irradiated 
C57BL/6 (H-2b) splenocytes in the presence () or absence () of 68 µM CA.  On day 5 
CTLs were harvested and plated with fluorescently labeled EL-4 (H-2d) target cells at 100:1 
and 50:1 effector to target ratios for 2 hours.  After 2 hours supernatants were harvested, 
mixed with Europium reagent, and fluorescence was measured.  Results are recorded in 
percent specific lysis as the mean (± SEM) of three independent experiments performed in 
triplicate.  **, p < 0.05 between the representative treated and untreated (control) group. 
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2.4.3  Redox modulation suppresses OT-1 CD8 T cell proliferation, IL-2, IFN-γ, TNF-α, 
and IL-17 production in a primary antigen-recall assay 
 
To determine if redox modulation of CD8 T cells could also affect CD8 T cell 
proliferation and adaptive immune effector function in the absence of CD4 T cell help, we 
utilized the CD8 T cell receptor transgenic OT-1 mouse model (79).  OT-1 splenocytes were 
incubated with 1 µM SIINFEKL peptide in the presence or absence of CA.  Redox modulation of 
primary OT-1 assays exhibited statistically significant decreases in proliferation on days 2 and 3, 
though a statistically significant decrease in IL-2 production was only achieved at day 3 (Figure 
12A, B).  This led us to speculate why redox modulation substantially inhibits proliferation 
whereas the effect on IL-2 production is not as drastic.   For this reason we examined IL-2 
receptor α-chain (CD25) expression on the surface of OT-1 CD8 T cells in a primary antigen 
recall assay.  We observed at least a three-fold decrease in CD25 expression on OT-1 T cells 
harvested from CA-treated OT-1 assays compared to untreated controls on days 2 and 3 (Figure 
13), pointing to a possible mechanism by which a several fold decrease in proliferation, though 
only slight reduction in IL-2 production could occur.  This phenomena, however, was not 
observed in the MLR model as the data demonstrated no significant difference in CD25 
expression in the presence or absence of redox modulation (Figure 14A,B). 
More importantly, IFN-γ synthesis was suppressed by redox modulation in primary OT-1 
assays compared to untreated assays at all time points (Figure 12C).  Additionally, redox 
modulation of OT-1 CTLs was associated with significant inhibition of TNF-α levels on days 1 
and 2 (Figure 12D), which may mechanistically contribute to decreased IFN-γ production.  
Interestingly, we also observed significant decreases in IL-17 in the presence of redox 
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modulation at all time points (Figure 12E), indicating that antigen-specific transgenic OT-1 CD8 
T cells exhibit TH1 and TH17 phenotypes having documented the production of both, IFN-γ and 
IL-17 (Figure 12E).  Taken together, these results clearly demonstrate that redox modulation has 
an inhibitory effect on CD8 T cell proliferation and adaptive immune effector function in the 
absence of CD4 T cell help. 
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Fig. 12.  Redox modulation suppresses proliferation and cytokine production in a 
primary OT-1 assay.  5 x 105 (A, D) or 105 (B, C) OT-1 splenocytes were incubated with 
1µM SIINFEKL in the presence () or absence () of 68 µM CA for 1 to 3 days.  On days 
2 and 3 proliferation was assessed by [3H] TdR incorporation (A).  On days 1, 2, and 3 
supernatants were harvested and IL-2 (B), IFN-γ (C), and TNF-α (D) were measured by 
ELISA.  Results are presented as the mean (± SEM) of four independent experiments 
performed in triplicate.  **, p < 0.05 between the respective treated and untreated (control) 
group. 
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Fig. 13.  Redox modulation inhibits IL-2 receptor α-chain (CD25) expression on OT-
1 Transgenic CD8 T cells.  105 OT-1 splenocytes were incubated with 1µM SIINFEKL 
in the presence () or absence () of 68 µM CA for 1 to 3 days.  On days 1, 2, and 3 
cells were harvested, washed, and results are graphed correlating to surface staining of 
CD8 x IL-2 receptor α-chain (CD25).  Results are representative of three independent 
experiments shown in the Supplement to Fig. 13. 
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Fig. 14.  Redox modulation has no effect on IL-2 receptor α-chain (CD25) expression 
on BALB/c T cells.  106 BALB/c splenocytes were incubated with 106 irradiated C57BL/6 
splenocytes in the presence () or absence () of 68 µM CA for 3 to 5 days.  On days 3, 4 
and 5 cells were harvested, washed, and results are graphed correlating to surface staining of 
(A) CD4 x IL-2 receptor α-chain (CD25) or (B) CD8 x IL-2 receptor α-chain (CD25).  
Results are representative of three independent experiments shown in the Supplement to 
Fig. 14.    
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2.4.4  Redox modulation impairs the ability of antigen-specific OT-1 cytotoxic lymphocytes 
(CTLs) to kill their corresponding antigen-expressing target cells  
 
Redox modulation, known to inhibit the innate immune-derived pro-inflammatory third 
signal, was efficient in suppressing adaptive immune effector cytokine synthesis in OT-1 
primary assays, but whether redox modulation also decreased CTL activity remained to be 
determined.  To explore this, OT-1 CTLs were generated in the presence or absence of CA and 
used as effectors against the OVA-expressing tumor cell line, EG.7 (H-2b), and the non-OVA-
expressing parent cell line, EL-4 (H-2b).  As expected, both CA-treated and untreated OT-1 
CTLs failed to exhibit significant specific lysis of the non-OVA-expressing EL-4 targets at a 
50:1 effector to target ratio (Figure 15).  At the same effector to target ratio, CA-treated OVA-
specific OT-1 CTLs exhibited a 3-fold decrease in specific lysis of the OVA-expressing EG.7 
cells compared to untreated OT-1 CTLs (Figure 15).  This cytotoxicity assay further 
demonstrates that redox modulation is having a profound effect on T cell receptor transgenic 
antigen-specific CD8 T cells by impairing their capacity to be direct effectors of antigen-specific 
target cell lysis. 
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Fig. 15.  Redox modulation diminishes the ability of antigen-specific OT-1 CTLs to kill 
their corresponding antigen-expressing target cells in a cytotoxicity assay.  OT-1 CTLs 
were generated by activating 5 x 106 C57BL/6 APCs with 1µg/ml LPS for three days, 
loading the APCs with 5 µM SIINFEKL for 30 minutes, washing several times, then plating 
the activated, loaded APCs with 2.5 x 106 OT-1 T cells in the presence () or absence () 
of 68 µM CA for 4 days.  On day 4 treated and untreated CTLs were harvested and plated 
with fluorescently labeled (non-expressing) EL-4 or (OVA-expressing) EG.7 target cells at 
50:1 effector to target ratio for 2 hours.  After 2 hours supernatants were harvested, mixed 
with Europium reagent, and fluorescence was measured.  Results are recorded in percent 
specific lysis and are presented as the mean of three independent experiments performed in 
triplicate (± SD).  **, p < 0.05 between the representative treated and untreated (control) 
group. 
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2.4.5  Cell toxicity is not a mechanism of immunoregulation by CA  
 
To ensure that CA-treatment does not inhibit effector function by an apoptotic 
mechanism, we performed assays to compare the viability of untreated and CA-treated samples.  
Experiments were preformed in the MLR model on days 1, 3, and 5.  Viability was assessed by 
trypan blue exclusion (Figure. 16A, C, E) and annexin V staining (Figure 16B, D, F).  We 
observed a significant increase in cell viability in CA-treated samples by trypan blue exclusion 
on days 1 and 5 (Fig. 16A and E) and by annexin V staining on days 3 and 5 (Figure 16D, F).  
There was no significant difference in cell viability at other time points for either assay.   
To specifically analyze CD8 T cell viability, we performed annexin V and CD8 double 
staining by FACS analysis.  In these experiments we observed no significant difference in 
annexin V positive CD8 positive T cells in the presence or absence of CA, though a trend for 
increased cell viability, as indicated by increased percentages of live cells, was present in CA-
treated samples compared to untreated control samples (Table 1).  Day 5 was specifically chosen 
for our alloantigen-specific cytotoxicity experiments since this day is the optimal time point for 
the generation of CTL from a primary MLR assay.  Taken together, the viability data indicate 
that redox modulation inhibits pro-inflammatory cytokine production and CTL target cell lysis, 
while promoting cell viability.  These results further support our hypothesis that redox 
modulation imparts regulatory capabilities by preventing the transition from expansion to 
effector function in the absence of cell death. 
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Fig. 16.  Redox modulation enhances cell viability.  In a primary MLR, 106 BALB/c 
splenocytes were stimulated with 106 irradiated C57BL/6 splenocytes in the presence or 
absence of 68 µM CA for up to 5 days.  On days 1, 3 and 5, viability was assessed by trypan 
blue exclusion (A, C, E) or annexin V staining (B, D, F).  Results are presented as the mean 
(± SEM) of three independent experiments.  **, p < 0.05 between the respective treated and 
untreated (control) group. 
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2.4.6  Induction of a regulatory population is not a mechanism of immunoregulation by CA 
 
To determine if redox modulation induces a classic regulatory population we assessed 
intracellular expression of Foxp3 and IL-10 production.  To analyze Foxp3 expression in T cell 
populations primary MLRs and OT-1 assays were performed.  Cells were harvested from MLR 
assays on days 3, 4 and 5 and at 18, 42, and 66 hours for OT-1 assays and T cells were surfaced 
stained for CD4 or CD8 and CD25 and then stained for intracellular Foxp3.  OT-1 T cells appear 
to show a trend for decreased Foxp3 expression in the presence of redox modulation, while CD4 
and CD8 T cells in an MLR assay show a slight, but negligible, increase in Foxp3 on days 3 and 
4 (Figure 17).  On day 5, CD4 and CD8 T cells show a prominent decline in any Foxp3 
population, regardless of CA-treatment.  Perhaps this phenomenon is an indication that the 
regulatory mechanisms have been overcome by the robust response to alloantigen (7). 
Table 1. CD8 T cell viability is not significantly affected by redox modulation 
 
% cells double-negative 
(live cells) 
annexin V 
single-positive 
CD8 single-
positive 
CD8/annexin V 
double-positive 
BALB 32.35 +/- 9.69 62.25 +/- 10.25 4.70 +/- 0.70 0.75 +/- 0.07 
BALB + CA 40.90 +/- 0.28 53.15 +/- 0.21 5.30 +/- 0.28 0.70 +/- 0.14 
MLR 25.00 +/- 4.24 71.35 +/- 3.32 2.25 +/- 0.63 1.45 +/- 0.35 
MLR + CA 25.90 +/- 4.67 69.15 +/- 5.87 3.30 +/- 0.85 1.60 +/- 0.28 
  
CD8 T cell viability is increased in the presence of redox modulation.  In a primary MLR, 106 BALB/c 
splenocytes were stimulated with 106 irradiated C57BL/6 splenocytes in the presence or absence of 68 µM CA 
for 5 days.  On day 3 cells were harvested, washed and stained with CD8 and annexin V.  Results are 
presented as a percentage of the cell population as the mean (± SD) of two independent experiments. 
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Fig. 17.  Redox modulation does not induce Foxp3 expression. In primary MLRs, 106 
BALB/c splenocytes were stimulated with 106 irradiated C57BL/6 splenocytes in the 
presence or absence of 68 µM CA for up to 5 days.  MLR cells were harvested on days 3-5, 
surface-stained with CD4/CD8 and CD25, and then stained intracellularly with Foxp3. 
Results are representative of three independent experiments shown in the Supplement to 
Fig. 17. 
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To further examine the induction of any regulatory mechanisms in the presence of redox 
modulation IL-10 production was also analyzed in primary MLR and OT-1 assays.  Supernatants 
were harvested from MLRs on days 1-5 and from OT-1 assays on days 1-3.  In both assays, no 
significant difference was found between untreated and CA-treated wells, though there is a trend 
of decreasing IL-10 production on days 3-5 of the MLR and on day 3 in the OT-1 assay (Figure 
18).  IL-10 production could not be detected in wells receiving no stimulation by alloantigen or 
peptide for MLR and OT-1 assays, respectively (data not shown).  These data demonstrate that 
redox modulation does not induce a regulatory T cell population or increased IL-10 production 
by any cell type.       
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Fig. 18.  Redox modulation does not 
induce increased IL-10 production.  
In a primary MLR, 106 BALB/c 
splenocytes were stimulated with 106 
irradiated C57BL/6 splenocytes in the 
presence () or absence () of 68 
µM CA for up to 5 days. 105 OT-1 
splenocytes were incubated with 1µM 
SIINFEKL in the presence () or 
absence () of 68 µM CA for up to 3 
days.  IL-10 production was 
measured by ELISA.  Results are 
presented as the mean (± SEM) of 
three independent experiments 
performed in triplicate.  **, p < 0.05 
between the respective treated and 
untreated (control) group. 
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2.4.7 Redox modulation hinders intracellular ROS production in CD8 T cells 
 
We have previously shown that CA can inhibit ROS production in APCs (26), and now 
want to determine if CA can also hamper ROS production in CD8 T cells.  T cell receptor 
transgenic OT-1 splenocytes were stimulated with cognate peptide in the presence or absence of 
redox modulation for 24 hours after which the cells were harvested and labeled with CD8 and 
CM-H2DCFDA, an intracellular indicator of reactive oxygen species, for FACS analysis.  The 
data demonstrate that CA inhibits ROS production as ROS could not be detected in OT-1 CD8 T 
cells stimulated with cognate peptide in the presence of redox modulation, while OT-1 CD8 T 
cells stimulated with cognate peptide in the absence of CA show almost a 7% increase in 
intracellular ROS production over the background (Figure 19). 
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Fig. 19.  Redox modulation inhibits CD8 T cell ROS production.  2 x 106 OT-1 
splenocytes were stimulated with 1 µM SIINFEKL or left unstimulated in the presence or 
absence of 68 µM CA in a primary OT-1 assay.  After 24 hours cells were harvested, 
stained with CM-H2DCFDA, washed, and then stained with CD8.  Results are presented 
as delta (Δ) percent CD8 x CM-H2DCFDA double positive cells with respect to un-
stimulated OT-1 controls.  Results are representative of three independent experiments. 
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2.4.8  Redox modulation decreases intracellular expression of IFN-γ , perforin, granzyme B 
and surface expression of CD107a (LAMP-1) on alloantigen-specific CTLs and OVA-
specific OT-1 CTLs   
 
CTL effector molecules were measured to determine how redox modulation controls 
alloantigen-specific and OVA-specific CTLs from killing their respective targets.  Specifically, 
we performed intracellular staining assays for IFN-γ, perforin, and granzyme B expression and 
assessed degranulation using the surface marker CD107a (LAMP-1), on allospecific and OT-1 T 
cell receptor transgenic CTLs generated in an MLR or in an OT-1 primary assay, respectively.  
Analysis of intracellular IFN-γ levels in MLR and OT-1 primary assays demonstrated at 
least a 5-fold decrease in expression of IFN-γ-producing CD8+ T cells in CA-treated samples 
versus untreated controls (Figures 20A and 21A).  Perforin, granzyme B and CD107a (LAMP-1) 
expression was also notably inhibited by at least 5-fold on CA-treated CTLs versus untreated 
controls at all time points (Figures 20B-D and 21B-D).  These results indicate that redox 
modulation restrains allospecific and T cell receptor transgenic CTL target cell lysis by 
decreasing CTL effector molecule synthesis including IFN-γ, perforin, granzyme B, and the 
degranulation marker CD107a (LAMP-1), regardless of CD4 T cell help. 
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Fig. 20.  Redox modulation decreases intracellular expression of IFN-γ , perforin, 
granzyme B, and surface expression of CD107a (LAMP-1) on alloantigen specific 
CTLs.  Alloantigen-specific CTLs were derived by stimulating 106 BALB/c splenocytes 
with 106 irradiated C57BL/6 splenocytes in the presence () or absence () of 68 µM CA 
for 1, 2, or 3 days.  On days 1, 2, and 3 CTLs were harvested, washed, and results are 
graphed correlating to staining of surface CD8 x intracellular IFN-γ (A), surface CD8 x 
intracellular perforin (B), surface CD8 x intracellular granzyme B (C), or surface CD8 x 
surface CD107a (LAMP-1) (D). Results are representative of three independent experiments 
shown in the Supplement to Fig. 20A-D. 
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Figure 6 (A-D). Redox modulation decreases intracellular expression of IFN-γ, perforin, granzyme B,
and surface expression of CD107a (LAMP-1) on OT-1 CTL
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Fig. 21.  Redox modulation decreases intracellular expression of IFN-γ , perforin, 
granzyme B, and surface expression of CD107a (LAMP-1) on OT-1 CTLs.  OT-1 CTLs 
were derived by stimulating 105 OT-1 splenocytes with 1 µM SIINFEKL in the presence 
() or absence () of 68 µM CA for 1, 2, or 3 days.  On day 1, 2, and 3 OT-1 CTLs were 
harvested, washed, and results are graphed correlating to staining of surface CD8 x 
intracellular IFN-γ (A), surface CD8 x intracellular perforin (B), surface CD8 x intracellular 
granzyme B (C), or surface CD8 x surface CD107a (LAMP-1) (D). Results are 
representative of three independent experiments shown in the Supplement to Fig. 21A-D. 
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2.5  DISCUSSION 
 
A potential consequence of hindering CD4 T cell activation is a downstream effect on 
CD8 T cell effector function (94-98), therefore we examined if redox modulation could impact 
CD8 T cell effector function, either in the presence or absence of CD4 T cell help.  Our data 
demonstrate that redox modulation inhibits a response to alloantigen and a CD8 T cell receptor 
transgenic T cell response as exemplified by reduced proliferation, IL-2, IFN-γ, TNF-α and IL-
17 production.  More importantly, redox modulation significantly impaired antigen-specific CTL 
target cell lysis and the synthesis of cytolytic effector molecules, IFN-γ, perforin and granzyme 
B, as well as the expression of the surface degranulation marker, CD107a (LAMP-1).   
Using two robust in vitro experimental models, our data further support the pivotal role 
of redox status for generating a CD8 T cell effector response.  Furthermore, the results using the 
purified CD8 T cells from the OT-1 T cell receptor transgenic mouse demonstrate the likelihood 
that CD8 T cells, themselves, are directly affected by redox modulation.  The T cell precursor 
frequency involved in peptide recognition in an alloantigen mismatch is significantly elevated 
compared to that of nominal antigen recognition and the precursor frequency in a T cell receptor 
transgenic T cell population is elevated to an even higher degree over that of an allomismatch.  
Our experiments using CA to affect redox status were performed in the presence of increased 
precursor frequency in order to assess the efficacy of this type of regulation in two robust in vitro 
systems.   
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Interestingly, CA-treatment of the OT-1 primary recall assay had a profound effect on T 
cell proliferation, though IL-2 levels were not significantly inhibited at all time points (Figure 
12A and 12B).  Correlating with our previously published studies using human islets (38), our 
viability assays demonstrate that CA-treatment does not induce apoptosis, but leads to an 
increase in viable cells over the duration of the culture period (Figure 16 and Table 1).  In spite 
of the increased number of viable cells in CA-treated groups, pro-inflammatory cytokine 
production and cytotoxic lymphocyte (CTL) target cell lysis is hindered in the presence of CA 
(Figures 10, 11, 12, 15), indicating that CA is disrupting effector function in the absence of direct 
cell toxicity.   
Examination of IL-2 receptor α-chain (CD25) expression in CA-treated OT-1 assays 
exhibited greater than a 2-fold decrease in CD25 expression on days 2 and 3 (Figure 13).  The 
decrease in CD25 expression would impact the IL-2 autocrine loop resulting in a decrease in 
CD8 T cell proliferation.  Evidence indicating that CD25 expression is NF-κB-dependent (99-
101) taken together with our previous work in APCs, demonstrating that redox modulation 
inhibits NF-κB DNA-binding (48), leads us to speculate that this mechanism may be responsible 
for the decrease in proliferation in CA-treated OT-1 assays.  We did not observe a significant 
difference in CD25 expression in CA-treated mixed leukocyte reaction (MLR) assays (Figure 
14), however, a greater decrease in IL-2 production was observed (Figure 10B) compared to the 
CA-treated OT-1 assays (Figure 12B).  
The inhibition of cytokine production (IL-2, IFN-γ, TNF-α, IL-17) indicates that 
regulation by redox modulation is capable of overcoming a higher precursor frequency as 
compared to a nominal antigen (Figures 10 and 12).  Furthermore, this effect translated to a 
decrease in type 1 cytotoxic effector function, as demonstrated by a significant decrease in 
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extracellular and intracellular IFN-γ in MLR and OT-1 primary assays (Figures 10C, 12C,  20A, 
21A).  Impairing the production of IFN-γ is critical in suppressing undesirable immune responses 
as IFN-γ induces respiratory burst by macrophages, activates NF-κB, and induces MHC Class I 
expression (102).  In agreement with our previous studies using CD4 T cells (26), redox 
modulation significantly decreased TNF-α and IFN-γ production in allospecific and T cell 
receptor transgenic primary recall assay models (Figures 10C, 10D, 12C, 12D) and subsequently 
inhibited CTL antigen-specific target cell lysis (Figures 11 and 15).  In response to alloantigen, it 
is likely that impaired CD4 T cell function by redox modulation abates the availability of CD4 T 
cell help that enhances CD8 effector function.  Since CD8 T cells are highly dependent on CD4 
T cell help for an optimal CTL effector response (77, 103, 104), antigen-specific CTL precursors 
are tolerized, instead of activated when CD4 T cell function is impaired (104). 
In addition to a decrease in the TH1 cytokine response (Figures 10C, 10D, 12C, 12D) we 
found that redox modulation has a dramatic effect on the pro-inflammatory TH17 cytokine, IL-
17.  IL-17 has been implicated in a variety of autoimmune diseases and in allograft 
transplantation (83-85, 88, 89, 105, 106).  With anti-IL-17 emerging as a potential therapeutic 
proven to ablate arthritis, experimental autoimmune encephalomyelitis, and allograft rejection in 
animal models (83, 87, 107-111), there is growing interest in further characterization of TH17 T 
cells in autoimmunity and allograft rejection.   In this study we report a significant reduction in 
IL-17 production in response to alloantigen with CA-treatment (Figure 10E).  Additionally, we 
have found that CD8 T cell receptor transgenic OT-1 T cells produce IL-17 in response to 
cognate peptide and that redox modulation can inhibit this production (Figure 12E).   
Since our previous work revealed that redox modulation inhibits TNF-α, IL-1β and ROS 
production in LPS-stimulated murine macrophages by inhibiting NFκB-DNA binding (48), it is 
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probable that redox modulation is limiting IL-17 production by impeding a pro-inflammatory 
feedback loop involving NF-κB, IL-17, and NO, in addition to hindering optimal synergistic 
TH17 activation by suppressing ROS, IFN-γ, TNF-α and IL-1β production (26, 48, 84, 112-114).  
In combination with the previously cited literature, our data suggest that inhibition of NF-κB, 
and therefore, the innate-derived pro-inflammatory third signal (TNF-α, IL-1β, ROS) by redox 
modulation can efficiently hinder IL-17 production.  Using two robust in vitro models, our work 
reveals that redox modulation of pro-inflammatory third signal synthesis can affect both CD4 
and CD8 T cell effector function leading to a reduction in TH1 and TH17 pro-inflammatory 
cytokine synthesis and CTL effector molecules necessary for target cell lysis.  
Furthermore, we observed several-fold decreases in target cell lysis and the expression of 
the cytolytic effectors, perforin and granzyme B, and in the expression of the surface 
degranulation marker, CD107a (LAMP-1) on CA-treated alloantigen-specific CTLs (Figure 20B-
D).  To further delineate how redox modulation affects CD8 T cells, we generated antigen-
specific OT-1 CTLs.  We isolated the effect of redox modulation on CD8 T cells one step further 
since C57BL/6 APCs were pre-activated with LPS and pulsed with SIINFEKL, separately, prior 
to incubation with naïve OT-1 CD8 T cells (CTL generation) and CA-treatment.  In this 
experiment, the activated APCs were capable of producing pro-inflammatory third signal 
cytokines and to up-regulate co-stimulatory molecule expression for 3 days prior to CD8 
interaction and CA-treatment.  Addition of naïve OT-1 T cells and CA to the activated, 
SIINFEKL-pulsed APCs demonstrated that redox modulation was able to efficiently decrease 
CTL target cell lysis in the presence of pre-activated antigen-pulsed APCs (Figure 15).  
Additionally, redox modulation inhibited the expression of perforin, granzyme B, and CD107a 
(LAMP-1) in the presence of CA (Fig. 21B-D) quite possibly by inhibiting the NF-κB-dependent 
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expression of co-stimulatory molecules.  By impairing NF-κB activation and subsequent 
production of pro-inflammatory third signal cytokines, it is likely that redox modulation reduces 
APC maturation/up-regulation of CD40, CD80 and CD86, resulting in suboptimal signal 2 
interaction and ineffective activation of naïve T cells.  This hypothesis is currently under 
investigation in our laboratory, though the possibility that redox modulation has a direct effect on 
the T cell cannot be overlooked.    
The immunomodulatory capabilities of redox modulation on APC function have been 
described (48), however, a mechanistic analysis of the effect of redox modulation on T cells has 
not been fully characterized.  We have initiated studies to investigate the possible T cell 
mechanisms altered by redox modulation and hypothesize that CA-treatment can directly affect 
CD4 and CD8 T cells by inhibiting NF-κB-DNA binding (48), or by impairing T cell receptor 
signaling and/or STAT pathway activation.  Evidence that redox modulation may have an impact 
on T cell-specific signaling pathways was demonstrated when we observed decreased 
intracellular expression of IFN-γ in both CA-treated CTL models (Fig. 20A; Fig. 21A).   
Moreover, it has been demonstrated that IFN-γ production is required for optimal perforin-
mediated CTL effector function (115, 116), suggesting that redox modulation inhibits perforin-
mediated CTL target cell lysis, in part, by inhibiting IFN-γ production (Figures 10C, 12C, 20A, 
21A).   
Redox modulation of aberrant immune function is emerging as a viable immunotherapy 
since (a) oxidative stress contributes to allograft failure by triggering activation of the innate 
immune system (117), (b) redox modulation inhibits the pro-inflammatory innate immune-
derived third signal required for CD4 T cell adaptive immune maturation and effector function 
(48), (c) induces antigen-specific hypo-responsiveness (26), (d) suppresses CD8 T cell 
53 
proliferation (CPM and IL-2), (e) inhibits the synthesis of pro-inflammatory cytokines (IFN-γ, 
TNF-α, IL-17), and (f) impairs CTL target cell lysis by depressing CD8 CTL effector 
mechanisms (perforin, granzyme B, CD107a (LAMP-1)), and quite possibly, CTL generation.  
Agents such as CA, which affect immune function through redox modulation, may be alternative 
therapeutics to use in conjunction with decreased doses of late stage co-stimulatory blockade 
agents or calcineurin inhibitors to combat both innate and adaptive immune responses in 
transplantation. 
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3.0  CHAPTER 3:  REDOX MODULATION PROTECTS 
ISLETS FROM TRANSPLANT-RELATED INJURY 
 
 
3.1  ABSTRACT 
 
Due to reduced antioxidant defenses, β-cells are especially vulnerable to free radical and 
inflammatory damage.  Commonly used anti-rejection drugs are excellent at inhibiting the 
adaptive immune response, however, most are harmful to islets and do not protect well from 
reactive oxygen species (ROS) and inflammation resulting from islet isolation and ischemia-
reperfusion injury.  The aim of this study is to determine if redox modulation, using the catalytic 
antioxidant (CA), FBC-007, can improve in vivo islet function post-transplant.  The abilities of 
redox modulation to preserve islet function were analyzed using three models of ischemia-
reperfusion injury:  1) streptozotocin (STZ) treatment of human islets, 2) a STZ-induced murine 
model of diabetes, 3) a murine model of syngeneic islet transplantation; and one murine model of 
MHC-mismatched allogeneic transplantation.  CA-treatment of human islets protects from STZ-
induced islet damage and systemic delivery of CA ablates STZ-induced diabetes in mice.  Islets 
incubated with CA prior to syngeneic transplant exhibited superior function in an intraperitoneal 
glucose tolerance test (IPGTT) compared to untreated controls.  Allograft rejection was 
significantly delayed when CA-treated islets were transplanted into MHC-mismatched murine 
diabetic recipients and treating recipients systemically with CA further extended the delay in 
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allograft rejection.  Pre-treating donor islets with CA protects from antigen-independent 
ischemia-reperfusion injury incurred during transplantation.  Treating systemically with CA 
protects islets from antigen-independent ischemia-reperfusion injury and impairs the antigen-
dependent alloimmune response.  These results suggest that the addition of a redox modulation 
strategy would be a beneficial clinical approach to preserve islet function in transplantation.     
 
3.2  INTRODUCTION 
 
Hypoxia is the leading cause of β-cell death during islet isolation and transplantation (40) 
with the highest percentage of islet graft loss and dysfunction occurring just days after 
transplantation (118, 119).  Because islets are a cellular transplant, devoid of intrinsic vasculature 
(40, 120), they are exceptionally susceptible to ischemia-reperfusion injury.  Islets are also 
increasingly vulnerable since they have inherently decreased antioxidant capacity (17-22), 
making them prone to oxidative/nitrosative/free radical damage.  The antigen-independent 
complexities of islet transplantation increase the incidence of primary graft non-function and β-
cell death thus requiring protection for islets at early stages of the transplant procedure (121).  
In addition to antigen-independent innate-mediated inflammatory injury, islet allografts 
are also plagued by the antigen-dependent T-cell mediated alloimmune response, which 
necessitates immunosuppressive drugs for allograft survival.  Commonly used anti-rejection 
drugs are excellent at inhibiting the antigen-dependent adaptive immune response, though most 
are harmful to islets and do not protect well from antigen-independent reactive oxygen species 
(ROS) and inflammation during islet isolation and ischemia-reperfusion injury (15, 23, 122).  In 
their review, Balamurugan, et. al. concluded that successful islet transplantation in type 1 
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diabetes (T1D) necessitates islet-sparing immunosuppressive agents that combat recurrent 
autoimmunity with low islet toxicity (15).  Predominantly, the field of islet transplantation is 
devoid of cytoprotective agents that promote islet survival and function by inhibiting nonspecific 
innate-mediated inflammation during islet isolation and early inflammatory events in islet 
transplantation (7, 15, 16, 38, 39, 44, 121). 
The first phase of immunity involves innate immune activation and subsequent pro-
inflammatory signals required for optimal T cell activation (26-28), yet the majority of 
immunosuppressive drugs only target adaptive immune function (1, 7), the second phase of 
immunity.  A nontoxic, cell-permeable catalytic antioxidant (CA) redox modulator, FBC-007 
(manganese (II) tetrakis (N-ethylpyridium-2-yl) porphyrin) is able to depress free radical and 
cytokine production by antigen presenting cells (APC) (48) and T cells in transgenic and 
allospecific mouse models (26, 123).  Additionally redox modulation inhibits CTL (cytotoxic 
lymphocyte) target cell lysis by reducing the production of intracellular cytolytic molecules 
(perforin and granzyme B) in a mixed leukocyte reaction without toxicity (123), preserves and 
promotes human islet function in vitro (38, 39), prevents the transfer of diabetes into young 
NOD.scid mice (49), and inhibits innate-immune NF-κB activation (48).  Thus, islet-sparing 
agents, which decrease the production of free radicals, and therefore, pro-inflammatory 
cytokines, may have a positive impact on islet function post-transplant. 
Since islet transplantation can benefit from agents that inhibit early inflammatory 
cascades to preserve islet function (44), we hypothesize that redox modulation holds potential as 
a therapy in islet transplantation to decrease the incidence of β-cell primary non-function.  In 
order to further test the effects of redox modulation we treated human islets with STZ in vitro 
and treated mice in vivo with STZ, both in the presence or absence of CA, to mimic the antigen-
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independent free radical and inflammatory damage of post-transplant ischemia-reperfusion 
injury.  To examine the effects of islet-directed CA-treatment on innate-mediated (antigen-
independent) primary islet non-function in vivo, we performed syngeneic (175 islets/recipient) 
islet transplants in diabetic mice and assessed islet function by fasting intraperitoneal glucose 
tolerance tests (IPGTT).  Lastly, we performed allogeneic (300 islets/recipient) islet transplants 
in diabetic recipients to assess islet function in the presence or absence of islet-directed or 
systemic redox modulation in the presence of both, innate (antigen-independent) and adaptive 
(antigen-dependent), immune responses.  Our results demonstrate that islet-directed and 
systemically delivered redox modulation are protective of islet function post-transplant. 
 
3.3  MATERIALS AND METHODS 
 
3.3.1  Human islets   
 
Human pancreata were obtained from CORE (Center for Organ Recovery and Education, 
Pittsburgh, PA) and were harvested using standard multi-organ recovery techniques and islets 
were isolated as previously described (38).   
 
3.3.2  Human islet experiments   
 
Islet preparations were cultured in flasks at 37°C in an atmosphere of 5% CO2 in 
humidified air in human islet medium containing CMRL-1066 (Gibco-BRL) medium 
supplemented with 10% FCS, 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM L-
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glutamine (Life Technologies, Grand Island, NY).  The islets were cultured for 3 days and hand-
picked on the 4th day using a dissecting microscope.  Groups of 60 hand-picked islets were 
randomly assigned to control and experimental groups.  Each group was sub-cultured in 60 x 15-
mm Falcon dishes at a concentration of 12 islets/ml for 8 hours in the previously described islet 
media.  The CA group was treated with 68 µM CA and the STZ group was treated with 11 mM 
STZ while the control group was cultured in islet media alone.  The group treated with CA and 
STZ was treated with 68 µM CA 20 minutes prior to the addition of 11 mM STZ.  
 
3.3.3  Human islet viability assays  
 
Islet viability was determined by simultaneous staining of live and dead cells using a two-
color fluorescence assay (acridine orange (green=live) and ethidium bromide (red=dead), Sigma, 
St. Louis, MO).  After the 8-hour incubation, islets from each group were transferred into 
separate microcentrifuge tubes, washed with PBS, and spun at 2000 rpm for 2 minutes.  
Supernatants were carefully aspirated, leaving ~ 25 µl to allow re-suspension of the cell pellets.  
Next 1.3 µl of dye mix (100 µg/ml acridine orange + 100 µg/ml ethidium bromide in PBS) was 
added to each tube to stain all islet cell nuclei.  The tube was mixed gently, 25 µl of the cell 
suspension was transferred to a microscope slide, and a cover slip was placed on top of the 
suspension. Cells were visualized at 10x magnification using a fluorescence microscope with an 
excitation of 450-490nm.  At least 3 fields from each group were analyzed by ImageJ (NIH, 
Bethesda, MD) software.  The percentage of viable and dead cells was determined by linearly 
converting ImageJ arbitrary units into percentages.   
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3.3.4  Mice  
 
Male 6-8 week old C57BL/6 and BALB/c mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  C57BL/6-Ins2akita/+ breeder pairs (female C57BL/6 + male 
C57BL/6-Ins2akita/+) were also purchased from Jackson Laboratories, but bred in-house at the 
Rangos Research Center (Pittsburgh, PA).  Male C57BL/6-Ins2akita/+ mice develop 
spontaneous diabetes by 4 weeks of age and do not require exogenous insulin or 
fluids/electrolytes to thrive.  This strain is well-suited for transplantation studies because they 
become spontaneously diabetic, ease of care, and ability to be rendered indefinitely euglycemic 
via syngeneic islet transplants (300 C57BL/6 islets), yet reject islet transplants from MHC-
mismatched donors (300 BALB/c islets) (124).  
 
3.3.5  Systemic treatment with CA to inhibit STZ-induced diabetes   
 
C57BL/6 male mice were injected IP with 10 mg/kg CA for 7 days.  On day 2 all mice 
were given an intravenous (IV) injection of 170 mg/kg STZ.  Blood glucose was measured every 
other day.  Two consecutive blood glucose readings over 300 mg/dl were indicative of STZ-
induced diabetes.  Diabetic animals were sacrificed following the second consecutive reading.   
 
3.3.6  Syngeneic transplants   
 
8-12 week old C57BL/6 males were used as donors and recipients.  Recipients were 
injected intraperitoneally (IP) with 240 mg/kg STZ (Sigma) on day 1.  Animals were tested for 
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diabetes using urine-test strips (Bayer) on day 3.  All diabetic animals received 1 unit of insulin 
(Lantus) and 500 µl Ringers solution on days 3-5.  On day 5, islets were isolated from naive 
donor C57BL/6 mice as described in (125).  The same day, islets were simultaneously picked, 
counted, and redistributed into petri dishes containing 175 islets each.  Each dish of islets 
contained islet media (10% heat-inactivated FBS, 2% Hepes [1M], 1% Penicillin/Streptomycin 
[10,000 mg/ml], 1 % L-glutamine [200mM], and 0.1% 2-β-mercaptoethanol [50mM] in RPMI 
sterile-filtered) alone or islet media plus 68 µM CA.  Treated and control islets were incubated 
for 24 hours at 37 degrees C and 5% CO2.  Non-fasting blood glucose levels were tested in 
recipient mice on day 6 by obtaining a small blood sample from the retro-orbital sinus.  Only 
animals with blood glucose 400 mg/dl and above were used as recipients in this study.  On day 6, 
each recipient was transplanted with 175 syngeneic CA-treated or untreated control islets 
inserted under the kidney capsule as described in (125).  Blood glucose was tested every other 
day.  All mice normalized post-transplant. 
On post-operative day 9 and 70, transplant recipients were subject to a fasting 
intraperitoneal glucose tolerance test (IPGTT).  Food was removed from the recipients’ cages 18 
hours prior to IPGTT with water available ad lib.  Mice were weighed and a baseline (zero 
minute) blood glucose was taken immediately before each recipient was injected with a 10 µl/g 
body weight dose of sterile-filtered 20% glucose solution in dH20.  Blood glucose readings were 
taken at 30, 60, 90, and 120 minutes post glucose injection.  Nephrectomies were performed on 
Day 77 as described in (126). 
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3.3.7  Islet-directed CA-treatment to delay allograft rejection   
 
Male C57BL/6 mice were used as transplant recipients and male BALB/c mice were used 
as islet donors.  C57BL/6 mice were rendered diabetic with an intraperitoneal (IP) injection of 
240 mg/kg STZ.  Recipients were prepared for transplant as previously described and islets were 
incubated in islet media alone or in islet media with 68 µM CA for 24 hours.  Three hundred 
CA-treated or control-treated BALB/c islets were transplanted under the kidney capsule of 
diabetic C57BL/6 recipients as previously mentioned.  All diabetic recipients became 
euglycemic post-transplant.  Blood glucose was checked every other day.  Two consecutive 
blood glucose readings over 400 mg/dl were indicative of allograft rejection.  Diabetic animals 
were sacrificed following the second consecutive reading.       
   
3.3.8  Systemic delivery of CA in pellet form to delay allograft rejection   
 
Male C57BL/6-Ins2akita/+ mice were used as transplant recipients and male BALB/c mice 
were used as islet donors.  This work is based on (124) and the transplants were performed as 
previously mentioned, transplanting 300 BALB/c islets into each spontaneously diabetic 
C57BL/6-Ins2akita/+ recipient on day 0.  Three days before transplant, a placebo or 21-day CA 
pellet (0.1 mg/day or 5 mg/kg/day) (Innovative Research of America, Sarasota, FL) was inserted 
into each recipient.  An additional pellet was inserted into mice on post-operative day 16, as 
pellets were administered every 20 days.  All diabetic recipients became euglycemic post-
transplant.  Blood glucose was checked every other day.  Two consecutive blood glucose 
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readings over 400 mg/dl were indicative of allograft rejection.  Diabetic animals were sacrificed 
following the second consecutive reading.  
 
3.3.9  Hematoxylin and eosin (H&E) staining of islet-bearing kidneys  
  
Mouse kidney samples were fixed in 4% paraformaldehyde for 3hrs then transferred to 
30% sucrose.  After imbedded in frozen section medium (Richard-Allan Scientific, Kalamazoo, 
MI.), cryosections (10µm) were cut using a cryostat (Microm HM550, Germen) and mounted 
onto gelatin coated or pre-cleaned slides.  Hematoxylin and eosin staining was performed on pre-
cleaned slides using a Frozen Section Staining kit (Thermo Electron Corporation, Pittsburgh, 
PA).  Images were captured at 40x magnification using a Nikon confocal microscope (Nikon D-
ECLIPSE C1, Japan). 
 
3.3.10  Statistical analysis   
 
Mean data are expressed as standard error of the mean (SEM).  The difference between 
mean values was determined by a Student t test and the area under the curve was determined 
using the trapezoidal rule.  Kaplan-Meier survival plots were analyzed by the Log-rank test. All 
statistical analysis was performed with the aid of PRISM (Graphpad, San Diego, CA) and JMP 
statistical software from the SAS institute using p<0.05 to achieve significance.  
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3.4  RESULTS 
 
3.4.1  CA protects human islets from STZ-induced cell death  
  
Using STZ to mimic free radical damage and inflammation in ischemia-reperfusion 
injury human islets isolated from donor pancreata were divided into 4 groups and were cultured 
in 1) media alone (untreated), 2) CA, 3) STZ, or 4) CA+ STZ.  After an 8-hour incubation, a 
double-fluorescence viability assay was performed using acridine orange, which penetrates the 
plasma membrane of living cells and stains their nuclei green, and ethidium bromide, which only 
penetrates dead cells, in which membrane integrity is compromised, to stain their nuclei red.  
Panels in Figure 22A are representative fluorescent images from each treatment group with 
correlating to data analysis graphed in Figure 22B and exact percentages and significance listed 
below the graph.  We observed a significant increase in live cells with CA treatment (74.99 +/- 
8.59%) compared to untreated control islets (41.64 +/- 3.38%) and a substantial decrease in 
viability was recorded when islets were treated with STZ (20.02 +/- 0.65%).  As we 
hypothesized, islets treated with STZ in the presence of CA were comparatively more viable 
(63.24 +/- 5.99%), demonstrating a significant increase in cell viability versus islets treated with 
STZ alone (Figure 22B).  These data indicate that the addition of CA increases viability of 
human islets when used in the media alone, and even more significantly, when islets are treated 
with CA using STZ-treatment as a model of free-radical induced cell death.   
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A 
      UNTREATED         CA
        STZ CA STZ
 
 
B 
% LIVE CELLS 
 
P-VALUE 
 
UNTREATED (41.64 ± 3.38) vs. CA (74.99 ± 8.59) 
 
.0229 
 
STZ (20.05 ± 0.65) vs. UNTREATED (41.64 ± 3.38) 
 
.0103 
 
STZ (20.05 ± 0.65) vs. CA STZ (63.24 ± 5.99) 
 
.0089 
 
 
 
 
Fig. 22. CA protects human islets from STZ-induced cell-death. Human islets (60 
islets/group) were cultured in media alone, 68 µM CA, 11 mM STZ, or 68 µM CA + 11 
mM STZ.  A: Representative images of each group of islets after an 8-hour incubation, 
stained with acridine orange (green/live) and ethidium bromide (red/dead), then visualized 
under a fluorescence microscope at 10x magnification. B: The percentage of live and dead 
islet cells from A was assessed by Imagej software and the data is summarized in the table 
below B.  Open bars = live cells (n ≥ 3) and black bars = dead cells (n ≥ 3). Data are 
presented as means (+/- SEM). Significance was tested using Student t tests (*p<0.05). 
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3.4.2  Systemic treatment with CA inhibits streptozotocin-induced diabetes   
 
Streptozotocin (STZ) induces diabetes through a nitric oxide free radical mechanism 
resulting in DNA damage and islet cell death (127).  Since CA can inhibit free radical damage 
(26, 48, 123, 128) we wanted to determine if systemic CA-treatment could protect islets from 
STZ-induced islet cell death in vivo.  Five C57BL/6 mice were injected with 10 mg/kg CA daily 
for 7 days and 10 C57BL/6 mice were used as untreated controls.  On day 2 all mice were 
injected with STZ.  As shown in Figure 23, 90% of untreated mice (9/10) succumbed to STZ-
induced islet cell death and subsequent diabetes (2.3 +/- .6 days) while none of the CA-treated 
mice (n=5) developed diabetes (>120 days) (Log-rank p=0.005).  These results demonstrate that 
systemic treatment with CA protects islets from free radical damage to prevent STZ-induced 
diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23. Systemic CA-treatment inhibits STZ-induced diabetes. Mice received CA-
treatment on days 1-7 and STZ was given on day 2. Black squares = untreated (n=9); 
Black triangles = CA-treated (n=5). Significance was tested using the Log-rank test 
(p=.0005). 
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3.4.3  Islets incubated with CA prior to syngeneic transplant exhibit increased function by 
intraperitoneal glucose tolerance test (IPGTT)   
 
Based on previously published data demonstrating improved islet mass, viability, and 
function when human islets are treated with CA during isolation or in culture (38, 39), we 
wanted to determine if islet-directed CA can improve graft function in a syngeneic transplant 
model.  Diabetic C57BL/6 recipients were transplanted with 175 syngeneic islets, which were 
previously incubated in the presence (n=5) or absence (n=5) of 68 µM CA for 24 hours.  All 
animals were rendered euglycemic post-transplant and sustained long-term euglycemia.  Post-
nephrectomy all transplant recipients reverted to diabetes (data not shown).  Fasting IPGTTs 
were performed on post-operative day 9 and day 70.     
Recipients of CA-treated islets demonstrated significantly improved glycemic-control at 
30 and 60-minute time points compared to untreated controls (Figure 24A), which correlates to a 
significant decrease in the area under the curve for recipients of CA-treated islets (Figure 24B).  
Specifically, the area under the curve for recipients of CA-treated islets was less than half 
(4,561.4 +/- 1054.2 min*mg/dl) of the area under the curve for recipients of untreated islets 
(10,828.8 +/- 1,336.1 min*mg/dl).  To observe any long-lasting affect of the CA-incubation on 
islet function, mice from each group were monitored long-term and another IPGTT was 
performed on day 70.  Although the 70-day IPGTT did not show statistical significance, the 
trend of improved glycemic control in recipients of CA-treated islets, namely at 30 and 60 
minutes, was maintained (Figure 24C).  These results are evidence that islet-directed CA-
treatment is able to suppress antigen-independent ischemia-reperfusion injury as demonstrated 
by improved islet graft function.   
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Fig. 24. Pre-treating islets with CA prior to syngeneic transplant improves islet 
function. Islets were incubated ± CA for 24 hrs then 175 untreated or CA-treated islets were 
transplanted into syngeneic recipients. A: Fasting IPGTTs were performed on post-
operative day 9.  Black squares/black line = untreated islets (n=5). Black triangles/red line = 
CA-treated islets (n=5). B: Area under the curve calculation for (A). C: Fasting IPGTT 
performed on post-operative day 70. Black squares/black line = untreated islets (n=3). Black 
triangles/red line = CA-treated islets (n=3). Significance was tested for A, B , and C using 
Student t tests (*p<0.05). 
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3.4.4  Islet-directed CA-treatment delays allograft rejection in an MHC-mismatched islet 
transplant model   
 
Next, we tested the ability of islet-directed redox modulation to improve islet allograft 
survival.  Since islet-directed CA-treatment can preserve islet function during antigen-
independent ischemia-reperfusion injury in a syngeneic transplant model (Figure 24) and in 
human islet isolation (38, 39), we wanted to determine if islet-directed redox modulation using 
CA could reduce normalization blood glucose or delay antigen-dependent allograft rejection.  
These experiments were performed using BALB/c (H-2d) donor islets incubated in the presence 
or absence of 68 µM CA for 24 hours.  After the 24 hour incubation 300 CA-treated or untreated 
islets were transplanted into diabetic C57BL/6 (H-2b) recipients.  
Post-transplant, CA-treated islets normalized recipients (n=5) to significantly lower blood 
glucose levels (73 +/- 2.61 mg/dl)  compared to recipients (n=5) of control treated islets (118.2 
+/- 8.35 mg/dl) (Figure 25A), indicative of an increase in early islet graft survival (p< 0.0001).  
Though all allograft recipients were eugylcemic for over 2 weeks, the recipients of CA-treated 
islets retained euglycemia, and thus, a functioning allograft, significantly (Log-rank, p=.0246)  
longer (26 +/- 0 days) than the recipients of untreated islets (22.3 +/- 2.5 days) (Figure 25B).  
Taken together, these data indicate that cytoprotection of islets using islet-directed CA-treatment 
alone can delay allograft rejection.   
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Fig. 25 Pre-treating islets with CA prior to allogeneic transplant improves islet 
function. Islets were incubated ± CA for 24 hrs then 300 untreated or CA-treated islets were 
transplanted into diabetic allogeneic recipients. A: Normalization blood glucose of 
recipients within 2 post-operative days; n of 5/group. Significance was tested using a 
Student t test (*p<0.05). B: Allograft survival of recipients; n of 3/group. Significance was 
tested using a Log-rank test (p=.0246).  Black  =  recipients of untreated islets. Red = 
recipients of CA-treated islets.  
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3.4.5  Systemic delivery of CA prolongs allograft function in an MHC-mismatched islet 
transplant model   
 
To determine if systemic administration of CA would equate to a more substantial delay 
in allograft rejection we transplanted 300 BALB/c islets into spontaneously diabetic C57BL/6-
Ins2Akita/+ mice (124).  In our colony, 7-8 week old diabetic C57BL/6-Ins2Akita/+ males have a 
blood glucose level of 580 +/- 19 mg/dl, which is comparable to the average blood glucose level 
(544 +/- 11 mg/dl) for the same mice housed at the Jackson Laboratory (Maine).  Three days 
before transplant a CA (21-day, 5 mg/kg/day) or placebo pellet was inserted into diabetic 
recipients.  All 10 recipient mice normalized post-transplant (125 +/- 16.94 mg/dl).  CA-treated 
recipients (n=5) displayed a significant increase (Log-rank, p=.0023) in graft function (25.60 +/- 
2.86 days) compared to untreated recipients (n=5) (14.40 +/- 0.25 days) (Figure 26A).  H&E 
sections of islet-bearing kidneys post-rejection demonstrate a pronounced infiltrate in untreated 
recipients and a sparse infiltrate in CA-treated recipients (Figure 26B), suggesting the delay in 
graft rejection with CA-treatment is associated with decreased migration of immune cells to the 
site of the graft.  These results demonstrate that systemic delivery of CA can delay graft rejection 
by depressing the cytotoxic free radical and inflammatory damage generated by the innate 
(antigen-independent) immune response and possibly by impacting the T-cell-mediated adaptive 
(antigen-dependent) immune response (26, 123) to hinder allograft rejection. 
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Fig. 26. Systemic CA-treatment delays allograft rejection.  On day 0 diabetic recipients 
were treated with a placebo or CA-pellet.  300 allogeneic islets were transplanted into all 
recipients on day 3. A: Allograft survival of recipients. Black = placebo pellet (n=5). Red = 
CA pellet (n=5).  Rejection table below A.  Significance was tested using a Log-rank test 
(p=.0023). B: Post-rejection H&E staining of representative sections of islet-bearing 
kidneys from untreated and CA-treated recipients.  
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3.5  DISCUSSION 
 
Allograft acceptance can be achieved using immunosuppressive drugs, though most 
drugs that inhibit T-cell-mediated graft destruction have the unfortunate side effect of islet 
toxicity and do not significantly protect islets from ischemia-reperfusion insults (15, 23, 122) 
leading to primary non-function and β-cell death.  Current literature in islet transplantation 
expresses a need for improved therapeutics that control rejection while preserving islet function 
through cytoprotection (7, 15, 38, 39, 44, 121, 129, 130).  Since redox modulation affects the 
innate and the adaptive immune responses (26, 48, 123) and demonstrates cytoprotection during 
human islet isolation (38, 39), we hypothesized that it may be a useful approach in islet 
transplantation.  Because only a fraction of transplanted islets survive ischemia-reperfusion 
injury (38, 39, 119), our current study utilized the well-described redox-modulator, CA, to 
determine if islet graft survival and function could be improved by inhibiting free radical and 
inflammatory damage.  
In this study CA protects islets from STZ-induced free radical damage, antigen-
independent inflammatory ischemic damage during syngeneic transplantation, and delays 
rejection in allogeneic transplantation.  Specifically, we used STZ-induced diabetes as a model 
of islet cell death and found that systemic delivery of CA protected all mice from STZ-induced 
diabetes (Figure 23) likely by increasing antioxidant defenses in islets to render them more 
resistant to STZ-induced free radical damage.  To isolate antigen-independent ischemia-
reperfusion injury in a transplant setting, we used a syngeneic transplant model to analyze the 
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effects of pre-treating islets with CA.  Data from the IPGTTs indicate that islet-directed CA 
protects islet function during antigen-independent inflammatory injury (Figure 24A-C).   
Antigen-independent injury by the innate immune system plays a larger role in allograft 
rejection than previously thought correlating to the activation state of the powerful redox-
dependent transcription factor, NF-κB.  NF-κB shapes the innate and adaptive immune responses 
(29, 41, 42, 60, 63, 65) by controlling a myriad of pro-inflammatory and pro-apoptotic genes in 
multiple cell types, including β-cells (131-133).  Our previously published work indicates that 
redox modulation using CA can hinder apoptotic and necrotic pathways by inhibiting NF-κB-
DNA binding, PARP activation, and the production of chemokines and cytokines in human islets 
(39).  In this study we expanded our previous work with human islets (38, 39) using STZ-
treatment in the presence or absence of redox modulation to mimic islet cell damage incurred 
during ischemia-reperfusion injury.   Our data demonstrates that redox modulation is protective 
in a robust setting of ischemia-reperfusion injury (Figure 22), likely by hindering the previously 
mentioned apoptotic and necrotic pathways.  Other studies have also sighted NF-κB in islet 
death, demonstrating that manipulating components of the NF-κB pathway can hinder its 
activation, and imminent inflammatory damage, to protect islets from apoptosis in autoimmunity 
and islet transplantation (133-135).  Since redox modulation using CA can enter mitochondria in 
vivo to impart antioxidant protection (128), preservation of mitochondrial function, and therefore 
ATP, is a potential mechanism by which CA protects from β-cell death (123).  Simultaneous use 
of systemically delivered redox modulation to treat the recipient (Figures 23 and 26) and islet-
directed CA to treat the donor islets (Figures 22 and 24) would limit β-cell exposure to cytokine 
and NO damage, thus hindering the hypoxic and inflammatory onslaught endured by islets 
during isolation and ischemia-reperfusion injury post-transplantation.  
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Moreover, Contreras et. al. notes that increasing islet yield post-isolation is paramount in 
order to propel the success of clinical islet transplantation, as the Edmonton protocol requires 1 
to 3 pancreata per recipient (14).  Currently, the demand for islets far outweighs the supply (14), 
especially since more than one islet infusion is frequently required to eliminate the need for 
exogenous insulin (12).  Since CA-treatment increased islet viability in human (in vitro) (Figure 
1) (38, 39) and murine (in vivo) (Figures 23-25) models of ischemia-reperfusion injury, CA-
treatment may allow a reduced number of islets (islet equivalents) needed to normalize a 
recipient.  The ability to decrease the number of human pancreata/islet infusions required to 
achieve long-term insulin-independence would overcome a major hurdle in islet transplantation 
(12, 14, 25).  Additionally, it has been reported that rodent islets suffer from decreased protection 
from oxidative stress compared to human islets (136).  This evidence suggests that our favorable 
results using redox modulation in murine models of transplantation may translate successfully to 
clinical transplantation.   
In addition to reducing primary islet  non-function (Figure 24), islet-directed CA-
treatment also demonstrated a protective effect in antigen-dependent allogeneic islet 
transplantation (Figure 25).  Comparatively, systemic delivery of CA (Figure 26) extends 
allograft rejection beyond islet-directed CA-treatment to support islet engraftment, viability, and 
function because CA can also act as an immunomodulatory agent by inhibiting APC activation 
(48), CD4 (26) and CD8 T cell effector function (123) and CTL target cell lysis by decreasing 
cytolytic effector molecule production in transgenic and alloreactive models (123).  However, in 
this study, we are not certain if the delay in allograft rejection is due to increased cytoprotection 
and preservation of islets by CA during ischemia-reperfusion injury (Figures 24 and 25) or as a 
result of immune-modulation correlating to decreased activation of the alloimmune-response. 
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Both scenarios resulting in a subsequent decrease in migration of immune cells to the sight of the 
graft in CA-treated recipients (Figure 26) and most likely, the delay in allograft rejection is a 
combination of the two.  
CA is known to promote islet (38, 39) and cell survival while inhibiting effector function 
(26, 123), however, studies examining the effects of redox modulation on β-cell proliferation and 
genes that regulate proliferation are yet to be performed.  Because CA inhibits primary 
immunogenic proliferation (26, 123) and sustains disruption of effector function, but does not 
significantly inhibit secondary expansion (26), redox modulation could be of benefit when 
coupled to non-calcineurin or mTOR targeted anti-proliferative drugs, like mycophenolate 
mofetil (MMF).  Additionally, if islets are treated with CA prior to transplant, they may be 
afforded increased protection from toxic immunosuppressives currently used in transplant 
protocols thereby increasing transplant success by limiting graft loss.  Redox modulation may 
also allow for the dose and duration of immunosuppressants to be weaned over a transplant 
recipient’s lifetime since CA protects from the inflammatory damage associated with islet 
isolation and transplantation.  Taken together, redox modulation is a favorable therapeutic to add 
to the currently administered immunosuppressives since CA is a nontoxic, non-immunogenic 
small molecule compound that offers the flexibility of systemic and/or tissue-specific treatment, 
ease of application, and a history of reproducible outcomes (26, 38, 39, 48, 49, 123, 128).  The 
reported benefits of CA-treatment for islets, autoimmunity and alloimmunity suggest redox 
modulation as a clinical approach, especially for diabetic recipients of islet allografts. 
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4.0  CHAPTER 4:  AN ANTIGEN-SPECIFIC NEGATIVE 
VACCINATION USING APOPTOTIC DONOR CELLS 
ADMINISTERED IN A NON-INFLAMMATORY 
ADJUAVANT INDUCES LONG-TERM ALLOGRAFT 
TOLERANCE  
 
 
4.1  ABSTRACT 
 
The many complications involved in islet transplantation yield poor outcomes limiting 
the procedure to adults with a history of extreme glucose dysregulation.  The main impediments 
restraining islet transplant success include islet primary non-function and repercussions on islet 
and recipient health resulting from nonspecific immunosuppression.  In this study we examined 
two methods to delay/prevent allograft rejection with the goal of reducing the previously 
mentioned pitfalls of islet transplantation.   Redox modulation, using a well-characterized small 
molecule catalytic antioxidant (CA), FBC-007, is the first approach we used.  CA improves islet 
function and viability, suppresses innate and adaptive immune activation, and is capable of 
achieving antigen-specific hyporesponsiveness.  We determined that this strategy is not harshly 
immunosuppressive and decreases activation and migration of immune cells to the site of the 
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islet allograft thus delaying allograft rejection.  The second strategy is a negative vaccination. 
We administered apoptotic donor splenocytes in a non-inflammatory adjuvant prior to islet 
transplantation to induce donor-specific tolerance.  This method proved even more successful 
than systemic CA-treatment as the negative vaccination tolerized recipients to allogeneic donor 
islets.  These results demonstrate viable therapeutic approaches using islet-sparing and antigen-
specific strategies to delay/prevent allograft rejection in an effort to minimize difficulties with 
islet transplantation.            
 
4.2  INTRODUCTION 
 
Currently, islet transplantation is limited to brittle diabetics (11) due to complications 
from harsh immunosuppressive therapy and a lack of long-term glycemic control post-transplant 
(12).  Though immunosuppressive drugs are efficient at inhibiting the T-cell mediated 
destruction of the donor islet graft, they are not cytoprotective, are associated with islet toxicity, 
and very rarely protect from nonspecific inflammation due to ischemia reperfusion injury (15, 
23, 122).  The current nonspecific regimen of immunosuppression can lead to complications 
including infection and malignancy requiring the recipient to stop immunosuppressants, upon 
which the recipients succumb to allograft rejection (13).  The outlook of islet transplantation in 
its present form is grim.  Only 5/36 subjects remained insulin-independent 2 years post-
transplant as reported in a trial of the Edmonton islet transplantation protocol (13).  In agreement 
with the literature, solutions to hurdles in islet transplantation can be found in therapies that are 
islet-sparing and/or antigen-specific to improve post-transplant outcomes (7, 15, 38, 39). 
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 In this study we analyzed the capabilities of two novel approaches in islet transplantation.  
The first approach focuses on cytoprotection for islets and immunomodulation of the alloimmune 
response using redox modulation.  Redox modulation by the catalytic antioxidant (CA), FBC-
007, has proven islet-sparing and immunomodulatory as demonstrated in our previous in vitro 
studies which detail the ability of CA to impair NF-κB activation in APCs (48) and to decrease 
CD4 (26) and CD8 T cell responses (123).  Additionally redox modulation enhances human islet 
function post-isolation (38, 39) and murine islet function versus nonspecific ischemia reperfusion 
injury post-transplant (Figure 24).  We have previously observed a delay in allograft rejection 
using systemic redox modulation (Figure 26), however the mechanism(s) responsible for in vivo 
protection from the alloimmune response have not been elucidated.   A focus of this study is to 
investigate the mechanism of CA’s immunomodulatory abilities in an in vivo model of 
allogeneic islet transplantation. 
 The second approach aims to treat transplant recipients in the absence of nonspecific 
immunosuppression using an antigen-specific negative vaccination approach.  The negative 
vaccination consists of apoptotic donor cells administered prior to allograft transplant in 
incomplete freund’s adjuvant (IFA).  It is well-known that apoptotic cells induce tolerance and 
evade immunity (29, 137, 138).  By educating the recipient immune system with apoptotic donor 
cells, in the absence of inflammation, DCs remain in the steady-state resulting in tolerance versus 
activation in response to donor alloantigen (5, 36).  Antigen is detectable for a minimum of one 
week when given in IFA (subcutaneously or intraperitoneally), suggesting that unresponsiveness 
is a result of a slow, persistent depot release of antigen compared to the fleeting persistence of 
antigen administered in PBS (139, 140).  Additionally, subcutaneously administered antigen is 
detectable longer than antigen given IV due to the route of administration affording a slow 
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release of antigen into the draining lymph nodes.  Subcutaneously delivered antigen can persist 
for several days allowing an extended period of time for the APCs to process and present antigen 
unlike quick clearance when antigen is in the circulation via an IV route of delivery (141).  Other 
methods using donor cells to delay allograft rejection have been preformed, but these strategies 
use live, chemically-treated or manipulated cells, with most protocols requiring the use of some 
form of immunosuppressant therapy in conjunction with the donor cells to achieve any delay in 
allograft rejection (43, 142-145).  Some groups have irradiated donor splenocytes while others 
give antigen in IFA (141), but never has there been an approach combining the two methods: 
using apoptotic donor cells administered subcutaneously in IFA to induce a depot delivery of 
apoptotic alloantigen in a non-inflammatory environment so the donor antigen can be processed 
as self-antigen by host APCs (5, 143) to induce tolerance.  Warren et al (1986) theorizes that the 
depot release of antigen is an attribute specific to adjuvants to induce an antigenic response, 
however, when a non-immunogenic antigen, like apoptotic donor cells, are delivered 
subcutaneously in a non-inflammatory adjuvant (IFA), we hypothesize that long-term antigen-
specific hyporesponsiveness will occur.  In this study we analyze the affects of CA-treatment and 
negative vaccination on the immune system in naïve mice and in an islet transplant setting to 
elucidate the mechanisms underlying the delay in allograft rejection. 
 
4.3  MATERIALS AND METHODS 
 
4.3.1  Mice  
 
Male 6-8 week old C57BL/6 (H2-b) and BALB/c (H2-d) mice were purchased from 
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Jackson Laboratories (Bar Harbor, ME).  All animal studies were approved and trials were 
conducted in accordance with the University of Pittsburgh Animal Care and Use Committee.  
 
4.3.2  Viability assays 
 
Spleens from BALB/c mice were harvested, homogenized, and lysed. Half of the 
splenocytes from each spleen remained untreated and the remaining cells were exposed to 3500 
rads using an x-ray machine.  Both groups of splenocytes were incubated in Complete 
Splenocyte Medium (DMEM supplemented with 10% heat-inactivated FBS, 10 mM Hepes 
buffer, 4 mM l-glutamine, 200 µM nonessential amino acids, 1 mM sodium pyruvate, 61.5 µM 
2-mercaptoethanol, and 100 µg/ml gentamicin (Invitrogen Life Technologies, Carlsbad, CA, 
USA)) under normal conditions (37°C at 5% CO2 in a humid air incubator) for 16 hours as cell 
death does not occur immediately after x-ray irradiation.  After incubation cells were harvested 
and stained with FITC-conjugated Annexin-V and Propidium Iodide according to the BD 
Annexin V-FITC Apoptosis Detection Kit I manufacturer’s protocol (BD Biosciences).  
Fluorescence was measured on a FACSCalibur (BD Biosciences).  
 
4.3.3  Mixed leukocyte reactions (MLRs) 
 
Unidirectional MLRs were performed by co-culture of 106 BALB/c splenocyte 
stimulators (treated with 3500 rad) with 106 C57BL/6 splenocyte responders as described by (80) 
with minor modification.  All MLRs were performed in 96-well, round-bottom plates in a final 
volume of 200 µl CM and incubated for 5 days under normal conditions. 
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4.3.4  In vitro analysis of the TH1 response after treatment with the therapeutic strategies 
 
C57BL/6 mice were used as “recipients” and BALB/c mice were used as “donors”.  To 
analyze the TH1 response when mice are treated with redox modulation C57BL/6 mice were 
injected with PBS or 10 mg/kg CA per day for 7 days.  On the 7th day, CA-treated and sham 
PBS-treated mice were sacrificed and the spleens were prepared for a unidirectional C57BL/6 
responder MLR as previously described.  To analyze the TH1 response when mice are treated 
with a negative vaccination 107 BALB/c splenocytes were irradiated at 3500 rads and mixed 1:1 
in IFA and delivered subcutaneously in C57BL/6 mice at the base of the tail in a volume of 100 
µl on day 1.  On day 7, untreated and negatively vaccinated mice were sacrificed and MLRs 
were preformed as previously described.  Supernatants of all MLRs were harvested on Days 1-5 
and IFN-γ ELISAs were performed.  
 
4.3.5  Cytokine measurements by ELISA  
 
MLR assays were performed as described above and supernatants were harvested on days 
1 through 5 to measure IFN-γ production by ELISA.  IFN-γ produced in supernatants of 96-well 
MLR assays were measured using antibody pairs from BD Pharmingen (San Diego, CA).  
ELISA plates were read on a Spectromax M2 microplate reader (Molecular Devices, Sunnyvale, 
CA) and data were analyzed using Softmax Pro v5.0.1 (Molecular Devices).   
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4.3.6  Islet allograft transplants   
 
8-12 week old C57BL/6 males were used as recipients and 8-12 week old BALB/c mice 
were used as islet donors.  Recipients received an intraperitoneal injection of 240 mg/kg 
streptozotocin (Sigma) on day 1 to induce islet cell death and subsequent diabetes.  Animals 
were tested for diabetes using urine-test strips (Bayer) on day 3.  All diabetic animals received 1 
unit of insulin (Lantus) and 500 µl Ringers solution on days 3-5.  On day 5, islets were isolated 
from naive donor BALB/c mice as described in (125).  The same day, islets were simultaneously 
picked, counted, and redistributed into petri dishes containing 150 islets each.  Each dish of islets 
contained islet media (10% heat-inactivated FBS, 2% Hepes [1M], 1% Penicillin/Streptomycin 
[10,000 mg/ml], 1 % L-glutamine [200 mM], and 0.1% 2-β-mercaptoethanol [50mM] in RPMI 
sterile-filtered). Islets were incubated up to 24 hours at 37 degrees C and 5% CO2. Non-fasting 
blood glucose levels were tested in recipient mice on day 6 by obtaining a small blood sample 
from the retro-orbital sinus.  Only animals with blood glucose 400 mg/dl and above were used as 
recipients in this study. CA-treated recipients were injected with 100 µl of 2mM CA 
subcutaneously beginning three days before islet transplant and were injected daily throughout 
the duration of the experiment.  Negatively vaccinated mice were injected subcutaneously at the 
base of the tail with 100 µl of a 1:1 mixture of 107 apoptotic BALB/c splenocytes to incomplete 
freund’s adjuvant (IFA) 7 days before the islet transplant.  Donor splenocytes were rendered 
apoptotic through exposure to 3500 rads using a γ-irradiator or x-ray machine and the negative 
vaccination was emulsified using a leur-lock syringe system (Hamilton) prior to injection.  Three 
hundred untreated BALB/c islets were transplanted under the kidney capsule of diabetic 
C57BL/6 recipients as previously mentioned.  All diabetic recipients became euglycemic post-
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transplant.  Blood glucose was checked every other day.  Two consecutive blood glucose 
readings over 400 mg/dl were indicative of allograft rejection. Diabetic animals were sacrificed 
following the second consecutive reading.  Some recipients, however, were sacrificed 14 days 
post-transplant.  Their kidneys were used for IHC and H&E staining, and their spleens were used 
for recall MLRs, for cytokine analysis. 
 
4.3.7  Immunohistochemical analysis 
 
Mouse kidney samples were fixed in 4% paraformaldehyde for 3 hours then transferred 
to 30% sucrose.  After being imbedded in frozen section medium (Richard-Allan Scientific, 
Kalamazoo, MI.), cryo-sections (10µm) were cut using a cryostat (Microm HM550, Germen) 
and mounted onto gelatin coated or pre-cleaned slides.  Sections were fixed in 2% 
paraformaldehyde for 5 minutes on gelatin-coated slides and then blocked with 20% normal goat 
serum for 1 hour at room temperature.  Primary antibodies included rat anti-F4/80 1:100 (Caltag 
Laboratories Inc, Burlingame, CA), rat anti-CD4 1:20, rat anti-CD8 1:20, hamster anti-CD11c 
1:30 (BD Biosciences, San Diego, CA).  Polyclonal rabbit anti-insulin (1:100) (Santa Cruz 
Biotechnology, Inc. Santa Cruz, CA) was double stained on these sections.  Slides were washed 
5 times in PBS and incubated with an Alexa Fluor 488 goat anti-rabbit (Molecular Probes, 
Eugene, OR), Cy3-conjugated goat anti-rat or goat anti-hamster (Jackson Immuno Research Lab, 
INC. West Grove, PA) secondary antibody.  Then, slides were washed 3 times in PBS and 
nuclear staining was preformed with Hoechst stain.  Next, slides were mounted with cover glass 
and images were captured at 20x magnification using a Nikon confocal microscope (Nikon D-
ECLIPSE C1, Japan).  
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4.3.8  Statistical Analysis   
 
Mean data are expressed as standard error of the mean (SEM).  The difference between 
mean values was determined by a Student t test and the area under the curve was determined 
using the trapezoidal rule.  Kaplan-Meier survival plots were analyzed by the Log-rank test. All 
statistical analysis was performed with the aid of PRISM (Graphpad, San Diego, CA) and JMP 
statistical software from the SAS institute using p<0.05 to achieve significance.  
 
4.4  RESULTS 
 
4.4.1  Treating splenocytes with 3500 rads induces apoptosis 
 
It is well-documented that apoptotic cells can induce tolerance as they present antigen in 
the absence of inflammation (5, 36, 137, 138).  To demonstrate that exposing cells to radiation 
induces apoptosis we performed a viability assay on untreated splenocytes or splenocytes which 
were exposed to a dose of 3500 rads (Figure 27).  After 18 hours in culture, the majority of 
untreated cells were live (74.86 +/- 0.80), while the majority of cells exposed to radiation were 
late apoptotic (94.94 +/- 0.39).   This data indicates that radiation induces apoptosis in over 90% 
of cells, making the cell preparation suitable for tolerance induction using irradiated donor cells, 
requiring no further manipulation or exogenous treatment with any reagent.  This data also 
demonstrates the negligible presence of necrotic cells (2.05 +/- 0.61), which are known to induce 
inflammation (137, 138).   
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Fig. 27.  Irradiation induces apoptosis in BALB/c splenocytes.  BALB/c splenocytes 
were untreated (white bars) or treated with 3500 rads (black bars).  Cells from both groups 
were plated at 106 cells/well in a 96 well plate.  18 hours later cells were harvested for a 
viability assay using Annexin V and PI.  The top panel shows a distribution of the cell 
populations, which were assigned groupings based on classical Annexin V and PI staining.  
The lower panel details the graph in the top panel showing specific p values.  Results are 
presented as the mean (± SEM) of three independent experiments.  **, p < 0.05 between the 
respective treated and untreated (control) group.   
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4.4.2  The TH1 response after treatment with the therapeutic strategies in naïve mice not 
receiving a transplant 
 
The TH1 response is the dominant component of the T-cell mediated alloimmune 
response that destroys donor allografts.  For this reason, the effect of our therapeutic strategies 
on IFN-γ production was analyzed in naïve animals prior to attempting our strategies in allograft 
transplantation.  We tested our therapeutic approaches by administering treatment to C57B/6 
mice and then sacrificing the animal 7 days later to perform in vitro MLRs to measure the 
production of IFN-γ in the supernatants as an indicator of  any effect on the TH1 response.  
Animals were untreated, sham injected with PBS, treated daily with 10 mg/kg CA for 7 days, or 
received a negative vaccination of irradiated BALB/c splenocytes in IFA given subcutaneously 7 
days prior to MLR (Figure 28).  Compared to untreated control mice, mice receiving daily CA-
treatment (Figure 28A) or the negative vaccination (Figure 28B) demonstrated a marginally 
significant decrease in IFN-γ production on day 5 of an MLR.  These data suggest that our 
therapeutic strategies are not immunogenic or harshly immunosuppressive. 
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Fig. 28.  In vivo treatment with CA or a negative vaccination is not immunogenic or 
harshly immunosuppressive.  C57BL/6 mice were injected with PBS daily for 7 days 
(n=4) (white bars) (A), treated with CA at 10mg/kg/day for 7 days (n=4) (black bars) (A), 
given a single negative vaccination with apoptotic BALB/c splenocytes in IFA on day 1 
(n=3) (checkered bars) (B), or untreated for 7 days (n=3) (white bars) (B).  On the 8th day, 
all mice were sacrificed and MLR assays were performed in a 1:1 ratio of stimulators and 
responders using irradiated BALB/c splenocytes as stimulators.  Supernatants were 
harvested on days 1-5 and IFN-γ ELISAs were performed.  Results are presented as the 
mean (± SEM) of at least three independent experiments.  **, p < 0.05 between the 
respective treated and untreated (control) group. 
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4.4.3  The negative vaccination strategy induces long-term allograft tolerance 
 
Next, we performed allograft transplants using BALB/c (H-2d) donor islets and diabetic 
C57BL/6 (H-2b) recipients to determine if our therapeutic strategies were capable of delaying or 
preventing allograft rejection (Figure 29).  On average, untreated control recipients rejected islet 
allografts in 22.0 +/- 0.73 days (n=6).  Recipients receiving a daily injection of CA, beginning 3 
days prior to transplant, demonstrated a significant delay (Log-rank, p=0.0005) in allograft 
rejection (33.83 +/- 1.51 days, n=6) compared to untreated controls.  Recipients treated with the 
negative vaccination (107 BALB/c splenocytes exposed to 3500 rads and emulsified in IFA) 7 
days prior to transplant reached the highest significance (Log-rank, p<0.0001) by maintaining 
islet allografts that sustained function in excess of 60 days (n=6).  These results demonstrate that 
redox modulation can delay allograft rejection, though the negative vaccination appears to be the 
more effective strategy to induce long-term allograft tolerance.      
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Fig. 29.  CA delays allograft rejection and a negative vaccination induces long-term 
allograft tolerance.  A:  Diabetic C57BL/6 mice were untreated (n=6) (black line), 
systemically treated with CA daily, beginning 3 days before transplant (n=6) (red line), or 
given a single negative vaccination of apoptotic BALB/c splenocytes in IFA 7 days prior to 
transplant (n=6) (blue line).  Log-rank was used to determine statistical significance between 
treated and untreated groups. B:  This table details mean day to allograft failure for each 
group presented as means (± SEM).  A “t” test was used to determine significance between 
treated and untreated groups and resultant p values are shown. **, p < 0.05 was used to 
determine significance between the respective treated and untreated (control) groups. 
 
Log-rank untreated vs. CA p=.0005 
Log-rank untreated vs. negative vaccination p<.0001 
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4.4.4  The TH1 response in recipients of the therapeutic strategies 14 days post-transplant 
 
In order to examine the effects of  redox modulation or the negative vaccination on the 
TH1 immune response in transplant recipients we used splenocytes from transplant recipients 14 
days post-transplant as responders and irradiated BALB/c splenocytes as stimulators in recall 
MLRs.  Upon secondary exposure to alloantigen in a  recall MLR, untreated recipients produced 
significantly amplified levels of IFN-γ compared to a primary MLR (Figure 30).  Recipients 
treated with CA responded to a secondary exposure of alloantigen with substantially decreased 
levels of IFN-γ compared to untreated recipients correlating with previously published work 
demonstrating the ability of redox modulation to induce antigen-specific hyporesponsiveness 
(26).  Recipients of the negative vaccination produced IFN-γ levels comparable to those in a 
primary MLR, though this recall MLR is actually generating a tertiary response to alloantigen.  
Recipients of the negative vaccination were first exposed to alloantigen 7 days before allograft 
transplant with the negative vaccination and then for a second time with the allograft transplant, 
itself.  Since the day 14 in vitro recall MLR is a tertiary response to alloantigen for recipients of 
the negative vaccination controlled IFN-γ levels served as predictors of long-term allograft 
tolerance for this treatment group.   
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Fig. 30.  CA-treatment or a negative vaccination can impair the TH1 response in a 
recall MLR 14 days post-allotransplant.  C57BL/6 recipients were untreated (n=2) (R1, 
R2) (black bars), treated with CA daily beginning 3 days prior to transplant (n=2) (red 
bars) (R3, R4), or given a negative vaccination of apoptotic BALB/c splenocytes in IFA 7 
days prior to transplant (n=1) (blue bars) (L1). On post-transplant day 14, all mice were 
sacrificed and recall MLR assays were performed using a 1:1 ratio of stimulators and 
responders using irradiated BALB/c splenocytes as stimulators. Supernatants were 
harvested on days 1-5 and IFN-γ ELISAs were performed. Each set of bars represents an 
individual recipient. The solid blue line represents the maximum IFN-γ response from 
naïve MLRs (n=3). 
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4.4.5  Immunohistochemical analysis of islet-bearing kidneys 14 days post-transplant 
 
To examine the cellular infiltrate at the site of the islet allografts, we performed 
immunohistochemical analysis on islet-bearing kidneys 14 days post-transplant.  For all sections, 
insulin is stained green and nuclear staining is blue.  In panel A (Figure 31), untreated recipients 
and recipients treated with the negative vaccination show a similar innate immune infiltrate of 
macrophages (F4/80), while stained sections of recipients treated daily with CA showed an 
overall decrease in peri-islet macrophage infiltrate.  To examine the T-cell  infiltrate, sections 
were stained with T cell specific antibodies.  We observed the presence of a CD4 T cell 
population in untreated animals.  Comparatively, recipients of the negative vaccination show a 
stronger presence of peri-islet CD4 T cells, and CA-treated recipients show the least amount of 
CD4 T cell infiltrate, as the only CD4 positive cells are on the periphery in the CA-treated 
sections (Figure 31B).  To assess the infiltrate of cells responsible for direct damage to islets, 
sections were stained with a CD8 T cell antibody.  Untreated recipients show the most 
pronounced presence and infiltrate of CD8 T cells, followed by a few CD8 T cells on the 
periphery for the negatively vaccinated recipients, and a barely detectable presence of CD8 T 
cells in recipients treated with CA (Figure 31C).  Immunostaining for recipients receiving CA-
treatment reveals a reduction in immune cell infiltrate, correlating with the delay in allograft 
rejection.  The data also suggests a regulatory component for CD4 T cells surrounding islets in 
recipients of the negative vaccination as this CD4 T cell population is associated with allograft 
tolerance.  
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Fig. 31.  Immunohistochemistry of islet-bearing kidneys 14 days post-transplant.  
C57BL/6 recipients were untreated, treated with CA daily beginning 3 days prior to 
transplant, or given a negative vaccination of apoptotic BALB/c splenocytes in IFA 7 days 
prior to transplant.  For all slides green = insulin and blue = dapi.  A:  red = F4/80, B: red = 
CD4, and C: red = CD8.  Sections shown are representative of respective groups. 
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4.6  DISCUSSION 
 
Poor outcomes in islet transplantation forces the clinic to reserve islet transplantation 
only for brittle diabetics with severe blood glucose dysregulation because transplant recipients 
often suffer an increase in systemic complications post-transplant in excess of those attributed to 
type 1 diabetes (13).  Current literature calls for improved cytoprotection for islets and antigen-
specific immunosuppressive therapies, which can be employed in the absence of nonspecific 
immunosuppressive agents.  The aim of this study was to introduce new approaches to old 
problems in islet transplantation in an attempt to improve islet transplantation protocols.  By 
reducing challenges of islet transplantation including the side effects of harsh, nonspecific 
immunosuppressive drugs, it is possible to make the procedure more consistent with outcomes of 
long-term insulin-independence.   
While the benefits of redox modulation have been widely reported (26, 38, 39, 48), the in 
vivo mechanism(s) responsible for immunomodulation by redox modulation have not been 
thoroughly examined in allograft transplantation.  The approach of negative vaccination using 
our therapeutic protocol is novel in that IFA alone does not induce tolerance (141, 146-149) thus 
indicating that alloantigen-expressing apoptotic BALB/c splenocytes are the tolerizing 
component of our negative vaccination therapy.  Irradiating donor splenocytes proved successful 
at achieving apoptotic donor cells (Figure 27) and our previous work with redox modulation 
characterizes its abilities to impair the immune response to alloantigen (123) and to augment islet 
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viability and function (38, 39).  Figure 28A demonstrates that systemic treatment with CA is not 
severely immunosuppressive, suggesting that CA-treatment will not induce chronic infection or 
malignancy.  Additionally, previous work with murine and human islets demonstrates that this 
agent is a nontoxic, cytoprotective, anti-inflammatory, and islet-sparing therapeutic (38, 39, 
123), which is not the case with currently used immunosuppressive drugs, which specifically 
target adaptive immune function and can impair islet viability and function.   
IFN-γ levels in the MLR assays from the negatively vaccinated mice (no transplant) are 
especially remarkable (Figure 28B), since the MLR is a secondary exposure to alloantigen as the 
first exposure is the negative vaccination.  This result is evidence that our negative vaccination 
strategy is capable of controlling TH1 immunity to donor alloantigen.  Typically a secondary 
response to antigen produces a substantially elevated response compared to that of a primary 
response (Figure 30).  After first using naïve animals to test our therapeutic strategies of systemic 
redox modulation and negative vaccination, these approaches were then tested in an in vivo 
model of transplant rejection where recipient mice were either untreated, injected with CA daily 
beginning 3 days prior to transplant, or treated with the donor-specific negative vaccination 7 
days prior to transplant (Figure 29).   
The negative vaccination strategy proved the most successful as none of the transplant 
recipients rejected their allogeneic islet transplant compared to recipients of redox modulation, 
which induced a delay allograft rejection for a significant period of time compared to untreated 
controls.  To analyze in vivo treatments prior to graft failure, we performed recall MLRs on a 
cohort of transplant recipients treated with one of our therapeutic protocols14 days post-
transplant to examine effects on the TH1 response by measuring IFN-γ levels.  The success rate 
of the allograft transplants did not correlate with the inhibition of IFN-γ (Figure 30) since CA-
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treatment only afforded a delay in rejection yet produced the lowest TH1 response.  Surprisingly, 
recipients of the negative vaccination maintained long-term allograft tolerance despite higher 
levels of IFN-γ in the recall MLR compared to recipients treated with CA (Figure 30).  The work 
of Markees, et al, and Konieczny, et al reveals that IFN-γ is required for graft acceptance, 
suggesting that our dosage of CA-treatment decreases IFN-γ levels to a range that may not be 
supportive of allograft tolerance (150, 151).  Though redox modulation alone appears insufficient 
to entirely ablate allograft rejection, CA has much potential to be added to currently utilized 
transplant protocols to achieve long-term allograft tolerance while minimizing complications for 
the recipient.  
The most notable difference in TH1 analysis when using redox modulation (no allograft 
transplant) (Figure 28A) and in TH1 analysis 14 days post-transplantation (Figure 30) is exposure 
to alloantigen (allograft transplant).  As reported in our previous work (26), redox modulation 
can induce antigen-specific hyporesponsiveness.  For example, when redox modulation is 
administered 3 days before transplant (exposure to alloantigen) a marked reduction in antigen-
specific effector function is achieved (Figure 30).  Taken together, in vivo treatment with CA 
prior to in vivo (exposure to alloantigen) induces antigen-specific hyporesponsiveness as 
demonstrated by a depressed TH1 response in the secondary MLR in Figure 30.  Comparatively, 
in vivo treatment with CA prior to a primary in vitro MLR does not result in robust 
immunomodulation to significantly suppress the TH1 response as naïve mice treated with CA 
only yielded a slight decrease in IFN-γ levels on day 5 of the MLR (Figure 28A).  Since the 
recipients of the in vivo negative vaccination (receiving no transplant) were exposed/tolerized to 
antigen with the vaccination itself, the in vitro MLR (Figure 28B) served as a secondary 
response.  The day 14 post-transplant MLR using responder splenocytes from recipients of the 
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negative vaccination assays a tertiary response since the transplant is the second exposure to 
alloantigen and the negative vaccination is the first (Figure 29).  In both secondary and tertiary 
MLRs for recipients of the negative vaccination, the TH1 response was the same, which further 
confirms induction of long-term allograft tolerance.  
More insight into the mechanisms responsible for the delay/prevention of allograft 
rejection using redox modulation and a donor-specific negative vaccination was presented with 
immunohistochemical analysis of immune cell populations (Figure 31A-C) 14 days post-
transplant.  A decreased macrophage infiltrate was observed in recipients of redox modulation, 
most likely due to impaired NF-κB signaling (48), while  an increase in macrophage (F4/80) 
staining was seen in untreated and negatively vaccinated recipients (Figure 31A).  These data 
demonstrate the ability of systemic CA to impair activation of the pro-inflammatory innate-
immune response resulting in fewer macrophages trafficking to the site of the islet graft in CA-
treated recipients.  The CD4 T cell infiltrate is peri-islet in untreated and negatively vaccinated 
recipients.  While the CD4 T cells are present in the CA-treated recipients, they appear to have 
migrated to a location a distance from the islet allograft (Figure 31B).  We observed a 
noninvasive peri-islet CD4 T cell infiltrate, suggesting a regulatory function for these CD4 T 
cells found at the site of the allograft in negatively vaccinated recipients, which did not reject 
their allograft.  The decreased infiltrate found in sections of CA-treated recipients suggests 
impaired activation and migration by immune cells.  Lastly, direct effectors of islet cell death, 
the CD8 T cell population, appear to be most prevalent in untreated recipients, undetectable in 
CA-treated recipients and sparse in recipients of the negative vaccination (Figure 31C).   
Taken together, the subcutaneous delivery of apoptotic cells in IFA in our protocol may 
be able to tolerize an increased number of T cells compared to IV delivery as Kearney et al 
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discovered that the total number of antigen-specific T cells in the lymph nodes following a 
subcutaneous injection were higher compared to IV or IP routes of delivery (141).  Negative 
vaccination succeeds in alloantigen-specific hyporesponsiveness (Figure 30) and achieves islet 
allograft tolerance (Figure 29), though it does not bolster function of the islet allograft or impair 
autoimmunity like redox modulation.  Based on previous studies, it is possible that systemic CA-
treatment could depress autoreactive T cell effector function (49) in addition to offering 
protection from alloimmunity for islets post-transplant, as shown in this study (Figure 29).  
Ideally, recipients of islet transplants should receive islets that are functionally more robust and 
protected from nonspecific inflammation (38, 39) while avoiding complications of non-specific 
immunosuppression to achieve antigen-specific long-term allograft tolerance.  A therapeutic 
protocol encompassing these requirements is especially applicable in islet transplantation using 
CA-treated islets from brain-dead donors and also in live kidney transplantation where peripheral 
blood leukocytes (PBL) can be easily harvested for the negative vaccination strategy, all in an 
effort to increase the probability of long-term islet allograft function.  
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SUPPLEMENTAL DATA FOR FIGURES 13, 14, 17, 20 & 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3
0
10
20
30
40
50
60
70
OT-1 + SIINFEKL
OT-1 + SIINFEKL + CA
DAY
1 2 3
0
10
20
30
40
50
60
70
DAY
1 2 3
0
10
20
30
40
50
60
70
DAY
 
Supplement to Fig. 13. Redox modulation inhibits IL-2 receptor α-chain (CD25) 
expression on OT-1 Transgenic CD8 T cells. Supplemental FACS data showing three 
similar experiments representing the trend shown in Fig. 13. 
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Supplement to Fig. 14A. Redox modulation has no effect on IL-2 receptor α-chain  
(CD25) expression on BALB/c T cells.  Supplemental FACS data showing three similar 
experiments representing the trend shown in Fig. 14A. 
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Supplement to Fig. 14B. Redox modulation has no effect on IL-2 receptor α-chain  
(CD25) expression on BALB/c T cells.  Supplemental FACS data showing three similar 
experiments representing the trend shown in Fig. 14B. 
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Supplement to Fig. 17. Redox modulation does not induce Foxp3 expression.  
Supplemental FACS data showing three similar experiments representing the trend shown in 
Fig. 17. 
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Supplement to Fig. 17. Redox modulation does not induce Foxp3 expression.  
Supplemental FACS data showing three similar experiments representing the trend shown in 
Fig. 17. 
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Supplement to Fig. 20A. Redox modulation decreases intracellular expression of IFN-γ  
in alloantigen-specific CTLs. Supplemental FACS data showing three similar experiments 
representing the trend shown in Fig. 20A.  
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Supplement to Fig. 20B. Redox modulation decreases intracellular expression of 
perforin in alloantigen-specific CTLs. Supplemental FACS data showing three similar 
experiments representing the trend shown in Fig. 20B.  
 
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3
0
1
2
3
4
5
6
7
8
9
MLR
MLR + CA
DAY
1 2 3
0
1
2
3
4
5
6
7
8
9
DAY
1 2 3
0
1
2
3
4
5
6
7
8
9
DAY
 
Supplement to Fig. 20C. Redox modulation decreases intracellular expression of 
granzyme B in alloantigen-specific CTLs. Supplemental FACS data showing three similar 
experiments representing the trend shown in Fig. 20C.  
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Supplement to Fig. 20D. Redox modulation decreases surface expression of CD107a 
(LAMP-1) on alloantigen-specific CTLs. Supplemental FACS data showing three similar 
experiments representing the trend shown in Fig. 20D.  
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Supplement to Fig. 21A. Redox modulation decreases intracellular expression of IFN-γ  
in OT-1 CTLs. Supplemental FACS data showing three similar experiments representing the 
trend shown in Fig. 21A.  
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Supplement to Fig. 21B. Redox modulation decreases intracellular expression of 
perforin in OT-1 CTLs. Supplemental FACS data showing three similar experiments 
representing the trend shown in Fig. 21B.  
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Supplement to Fig. 21C. Redox modulation decreases intracellular expression of 
granzyme B in OT-1 CTLs. Supplemental FACS data showing three similar experiments 
representing the trend shown in Fig. 21C.  
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Supplement to Fig. 21D. Redox modulation decreases surface expression of CD107a 
(LAMP-1) on OT-1 CTLs. Supplemental FACS data showing three similar experiments 
representing the trend shown in Fig. 21D.  
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CONCLUSIONS 
 
There have been several advances in islet transplantation over the last decade, however, 
many improvements must be made to ensure predictable long-term insulin-independence for 
allograft recipients.  Our studies were performed in an effort to increase graft function post-
transplant by refining the procedure of islet transplantation.  While we have elucidated the 
benefits of using redox modulation in islet transplantation, we suspect that redox modulation can 
be advantageous in other autoimmune and inflammatory diseases.  Redox modulation of immune 
function has great potential to reach the clinic for multiple uses including transplantation, 
autoimmune and inflammatory diseases, hypoxic injuries like stroke and heart attacks, cancer, 
and in degenerative disorders like Parkinson’s disease, Alzheimer’s disease and amyotrophic 
lateral sclerosis (ALS).  Redox modulation has been well characterized in innate immunity and 
innate-immune signaling, however, the effects of CA on adaptive immune signaling must be 
pursued in disease-related models to implement systemic use in humans.   
It is known that redox modulation induces “miseducation” of DCs by impairment of NF-
κB and 3rd signal of activation (26, 48), which has downstream effects on T cell activation (26, 
123).  In the presence of redox modulation, decreases in STAT4 and T-bet activation in CD4 T 
cells (Tse, unpublished data) and depression of CD3 expression in CD4 and CD8 T cells have 
been observed (Sklavos, unpublished data).  However, within the T cell, the effects of redox 
modulation on NF-κB activation and tyrosine phosphorylation, both essential for T cell 
activation, have not been thoroughly examined.  Previously we demonstrated that BDC-2.5 T 
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cells are not deleted in vivo when upon adaptive transfer into young NOD.scid mice after CA-
treatment (Piganelli, unpublished data).  CA-treatment does not induce anergy in T cells as 
secondary proliferative responses are in tact (26) nor does it induce a regulatory population based 
on invariable Foxp3 expression in CA-treated cells compared to untreated controls (Sklavos, 
unpublished data).  These data eliminate the possibility of an inducible T regulatory cell 
population arising in the presence of redox modulation.  Ignorance is not a possibility, as 
exposure to antigen is uninhibited in our in vitro studies and T cells come in contact with antigen 
in vivo, as evidenced by in vivo recall assays (26); (Sklavos, unpublished data).  Based on the 
aforementioned studies, redox modulation cannot be grouped under classical mechanisms. 
Further analysis of the negative vaccination strategy is also required as the mechanism(s) 
of tolerance has not yet been identified.  Anergy, regulation, and deletion of alloreactive T cells 
are all possibilities, though these mechanisms have yet to be tested.  In review of this body of 
work, redox modulation holds potential as a clinical therapeutic.  Since in vivo administration of 
CA depots in the liver, it would be an ideal therapeutic to use in islet transplantation as islets are 
infused into the portal vein to promote liver-engraftment.  Presently, redox modulation is being 
used as cytoprotection for islets in trials of xenograft transplantation with non-human primates.  
Though in early stages, studies treating porcine islets with redox modulation prior to transplant 
into non-human primates mirror results from our murine transplant models.  In both trials, 
recipients of CA-treated islets normalized to a lower blood glucose compared to recipients of 
untreated islets (Bottino, unpublished data).  Based on the success in non-human primates, the 
next step for redox modulation is as a cytoprotective agent for whole organ cold storage/islet 
isolation/culture in clinical transplantation.  Perhaps the first clinical work with redox 
modulation will be during islet isolation of autoislet transplants for patients with pancreatitis.  
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Based on our murine studies, redox modulation cannot be used as a monotherapy to inhibit 
allograft rejection.  However, there is potential for redox modulation to be used systemically, in 
combination with a decreased dose and/or duration of immunosuppressive agents to protect islets 
from the toxic effects of harmful anti-rejection agents.  This analysis of redox modulation using a 
small molecule catalytic antioxidant (CA) demonstrates that this strategy is effective as a 
cytoprotective and immunomodulatory approach that can be used in tissue-directed (islets 
incubated in CA), sustained-release pellet, or systemic form to improve islet function and impair 
allograft rejection of transplanted islets. 
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